Daniel James George
Professor of Medicine
Current Appointments & Affiliations
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2015
- Professor in Surgery, Surgery, Clinical Science Departments 2015
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2003
Contact Information
- Duke Box 103861, Durham, NC 27710
- GSRB 1 Room 3005, 905 S Lasalle St, Durham, NC 27710
-
daniel.george@duke.edu
(919) 668-4615
- Background
-
Education, Training, & Certifications
- Fellow in Medical Oncology, Medicine, Johns Hopkins University 1995 - 1998
- Medical Resident, Medicine, Johns Hopkins University 1992 - 1995
- M.D., Duke University 1992
-
Previous Appointments & Affiliations
- Associate Professor in Surgery, Surgery, Clinical Science Departments 2004 - 2015
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2015
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2011
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2003 - 2004
- Recognition
-
In the News
-
MAY 4, 2023 Duke Today -
MAY 12, 2021 Duke Health News -
MAR 23, 2021 Duke Health News -
JUN 4, 2018 Duke Health News -
NOV 9, 2015 WRAL -
AUG 26, 2015 Duke Translational Medicine Institute
-
- Research
-
Selected Grants
- Stellar-002: XL-092 +/- immunotherapy for genitourinary cancers awarded by Exelixis, Inc 2022 - 2027
- Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making awarded by National Institutes of Health 2022 - 2027
- DoD: PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2026
- A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas awarded by AstraZeneca Pharmaceuticals, LP 2021 - 2026
- PSMAfore: Lu-PSMA for men with castrate-resistant prostate cancer awarded by Novartis Pharmaceuticals Corporation 2021 - 2026
- Outcomes Database to prospectivelY aSSEss changing therapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) awarded by Pfizer, Inc. 2020 - 2025
- PSMAddition: Lu-PSMA in mHSPC awarded by Novartis Pharmaceuticals Corporation 2022 - 2025
- Trimodality Approach to Unfavorable Localized Prostate Cancer: a prospective trial of Neoadjuvant Pembrolizumab, ADT, and Prostate SBRT followed by Radical Prostatectomy awarded by Merck & Co., Inc. 2021 - 2025
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06940434 in Patients with Advanced or Metastatic Solid Tumors awarded by Pfizer, Inc. 2021 - 2025
- A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy awarded by Blue Earth Diagnostics 2020 - 2025
- An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer awarded by AstraZeneca Pharmaceuticals, LP 2020 - 2025
- ODYSSEY RCC awarded by Exelixis, Inc 2020 - 2024
- Odyssey RCC awarded by Merck Sharp & Dohme 2020 - 2024
- Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site awarded by Department of Defense 2021 - 2024
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) awarded by Calithera Biosciences, Inc. 2019 - 2024
- Targeting glutamine utilization in therapy-resistant prostate cancer awarded by Department of Defense 2021 - 2024
- Therapeutic targeting of MESH1 in renal cell carcinoma awarded by Department of Defense 2020 - 2023
- ODYSSEY RCC awarded by Bristol-Myers Squibb Company 2020 - 2023
- Race-related germline genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer awarded by Department of Defense 2019 - 2023
- Race-Related Alternative Splicing: Novel Targets in Prostate Cancer awarded by National Institutes of Health 2017 - 2023
- Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides awarded by Department of Defense 2020 - 2023
- Role of Implicit Bias on Outcomes of Advanced Cancer Patients awarded by Mount Sinai School of Medicine 2022 - 2023
- Eisai Educational Program - December awarded by Eisai, Inc. 2022
- A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies awarded by Janssen Pharmaceutica, Inc. 2017 - 2022
- Targeting RNA splicing in race-related aggressive and lethal prostate cancer awarded by Prostate Cancer Foundation 2018 - 2022
- Therapeutic targeting of cystine addiction of renal cell carcinoma awarded by Department of Defense 2019 - 2022
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2022
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2022
- An IND-enabling Trial to Determine the Number and Volume of Injections Necessary for Adequate Distribution Throughout Cancer Metastases and to Validate Poliovirus Receptor (CD155) Expression in Prostate Cancer awarded by V Foundation for Cancer Research 2016 - 2022
- Decreasing the Financial Burden for Patients with Advanced Prostate Cancer By Understanding Provider Decision-Making awarded by American Urological Association Foundation 2021 - 2022
- Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer awarded by V Foundation for Cancer Research 2016 - 2022
- A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer awarded by Janssen Pharmaceutica, Inc. 2017 - 2022
- Disparities in the Use of Oral Anticancer Agents in Kidney Cancer awarded by Yale University 2021
- A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center awarded by The Prostate Cancer Clinical Trials Consortium 2018 - 2021
- Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers awarded by V Foundation for Cancer Research 2019 - 2021
- ABI-RACE: A Phase II Open Label, Parallel group study of Abiraterone Acetate in African American and Caucasian Men with Metastic Castrate Resistant Prostate Cancer awarded by Janssen Pharmaceutica, Inc. 2013 - 2021
- Disparities in the Use of Oral Anticancer Agents in Kidney Cancer awarded by National Institutes of Health 2019 - 2020
- Validation and interrogation of differentially expressed and alternatively spliced genes in African American prostate cancer awarded by Department of Defense 2014 - 2020
- Prostate Cancer Outcomes: An International Registry awarded by Movember Foundation 2016 - 2020
- Race-related differential splicing of the insulin receptor and prostate tumor cell biology awarded by National Institutes of Health 2016 - 2020
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) awarded by Prostate Cancer Foundation 2014 - 2020
- BMS Bladder and Prostate Practicum 2019 awarded by Bristol-Myers Squibb Company 2019
- BAYER PROTOTYPE PROSTATE PROGRAM - 3 DAY PROGRAMMING awarded by Bayer Healthcare Pharmaceuticals Inc 2019
- Bayer-Exini Radium-223 Retrospective Study awarded by Bayer Healthcare Pharmaceuticals Inc 2016 - 2019
- A Phase I/II, Open-label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination with Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients with Advanced Cancer awarded by Celldex Therapeutics, Inc. 2015 - 2018
- Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy awarded by Department of Defense 2013 - 2017
- Aptamer Targeted Drug and Toxin Delivery to Prostate Cancer awarded by Department of Defense 2014 - 2016
- A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy awarded by Exelixis, Inc 2013 - 2016
- Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo awarded by Department of Defense 2012 - 2015
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors awarded by National Institutes of Health 2008 - 2014
- PRACTICUM - SANOFI 3 DAY DISEASE STATE TRAINING PROGRAM (PROSTATE, STEM CELL TRANSPLANT,LEUKEMIA /LYMPHOMA) awarded by Sanofi US 2014
- Prostate Cancer, Stem Cell Transplantation and Leukemia/Lymphoma Practicum awarded by Sanofi US 2014
- CTSA UL awarded by National Institutes of Health 2006 - 2012
- mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance awarded by National Institutes of Health 2007 - 2010
-
External Relationships
- American Association for Cancer Research
- Aptitude health
- AstraZeneca Healthcare Foundation
- Bayer Healthcare Pharmaceuticals
- Eisai
- Exelixis, Inc.
- IDEOlogy Health
- Janssen AI (Johnson & Johnson)
- Mashup Media
- Medscape ( WebMD HLTH Corp.)
- Merck
- Michael J Hennessey/OncLive
- Millenium Medical Publishing Inc
- Myovant Sciences, Inc
- Novartis pharmaceuticals
- OncoAI
- Pfizer Inc.
- Propella Therapeutics
- Sanofi Genzyme
- Up To Date Inc/Wolters Kluwer Health
- UroGPO
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Higano, C. S., D. J. George, N. D. Shore, O. Sartor, K. Miller, P. S. Conti, C. N. Sternberg, et al. “Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer (Accepted).” Eclinicalmedicine 60 (June 1, 2023). https://doi.org/10.1016/j.eclinm.2023.101993.Full Text
-
Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.” Clin Cancer Res 29, no. 10 (May 15, 2023): 1929–37. https://doi.org/10.1158/1078-0432.CCR-22-3233.Full Text Link to Item
-
Kaye, Deborah R., Hui-Jie Lee, Alexander Gordee, Daniel J. George, Peter A. Ubel, Charles D. Scales, and M Kate Bundorf. “Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.” Jco Oncol Pract 19, no. 4 (April 2023): e600–617. https://doi.org/10.1200/OP.22.00645.Full Text Link to Item
-
George, Daniel J., Fred Saad, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce Brown, et al. “Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.” Clin Genitourin Cancer, March 24, 2023. https://doi.org/10.1016/j.clgc.2023.03.009.Full Text Link to Item
-
George, Daniel J., Ateesha F. Mohamed, Jui-Hua Tsai, Milad Karimi, Ning Ning, Sayeli Jayade, and Marc Botteman. “Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.” Cancer Med 12, no. 5 (March 2023): 6040–55. https://doi.org/10.1002/cam4.5313.Full Text Link to Item
-
Gillessen, Silke, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, et al. “Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.” Eur Urol 83, no. 3 (March 2023): 267–93. https://doi.org/10.1016/j.eururo.2022.11.002.Full Text Link to Item
-
Butler, William, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J Spencer Hauck, Yinglu Zhou, et al. “Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.” Npj Precis Oncol 7, no. 1 (February 24, 2023): 22. https://doi.org/10.1038/s41698-023-00363-2.Full Text Link to Item
-
Hawkey, Nathan M., Amanda Broderick, Daniel J. George, Oliver Sartor, and Andrew J. Armstrong. “The Value of Phenotypic Precision Medicine in Prostate Cancer.” Oncologist 28, no. 2 (February 8, 2023): 93–104. https://doi.org/10.1093/oncolo/oyac198.Full Text Link to Item
-
Dzimitrowicz, Hannah E., Lauren E. Wilson, Bradford E. Jackson, Lisa P. Spees, Christopher D. Baggett, Melissa A. Greiner, Deborah R. Kaye, et al. “End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.” Jco Oncol Pract 19, no. 2 (February 2023): e213–27. https://doi.org/10.1200/OP.22.00401.Full Text Link to Item
-
Kase, Adam M., Daniel J. George, and Sundhar Ramalingam. “Clear Cell Renal Cell Carcinoma: From Biology to Treatment.” Cancers (Basel) 15, no. 3 (January 21, 2023). https://doi.org/10.3390/cancers15030665.Full Text Link to Item
-
Freedland, Stephen J., Krishnan Ramaswamy, Ahong Huang, Rickard Sandin, Jack Mardekian, Neil M. Schultz, Nora Janjan, and Daniel J. George. “Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.” Clinical Genitourinary Cancer, January 2023, S1558-7673(23)00022-8. https://doi.org/10.1016/j.clgc.2023.01.003.Full Text
-
Lim, Emerson A., Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, et al. “Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.” Clin Cancer Res 28, no. 22 (November 14, 2022): 4871–84. https://doi.org/10.1158/1078-0432.CCR-22-0612.Full Text Link to Item
-
Lillard, James W., Kelvin A. Moses, Brandon A. Mahal, and Daniel J. George. “Racial disparities in Black men with prostate cancer: A literature review.” Cancer 128, no. 21 (November 1, 2022): 3787–95. https://doi.org/10.1002/cncr.34433.Full Text Link to Item
-
Mucci, Lorelei A., Jacob Vinson, Theresa Gold, Travis Gerke, Julie Filipenko, Rebecca M. Green, Simon G. Anderson, et al. “IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.” Jco Glob Oncol 8 (November 2022): e2200154. https://doi.org/10.1200/GO.22.00154.Full Text Link to Item
-
George, Daniel J., Krishnan Ramaswamy, Ahong Huang, David Russell, Neil M. Schultz, Nora Janjan, and Stephen J. Freedland. “Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?” Future Oncol, October 13, 2022. https://doi.org/10.2217/fon-2022-0539.Full Text Link to Item
-
Motzer, Robert J., Jean-François Martini, Xinmeng J. Mu, Michael Staehler, Daniel J. George, Olga Valota, Xun Lin, Hardev S. Pandha, Keith A. Ching, and Alain Ravaud. “Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.” Nat Commun 13, no. 1 (October 10, 2022): 5959. https://doi.org/10.1038/s41467-022-33555-8.Full Text Link to Item
-
Brown, Landon C., Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.” J Immunother Cancer 10, no. 10 (October 2022). https://doi.org/10.1136/jitc-2022-005249.Full Text Open Access Copy Link to Item
-
Bu, Jiyoon, Woo-Jin Jeong, Roya Jafari, Luke J. Kubiatowicz, Ashita Nair, Michael J. Poellmann, Rachel S. Hong, et al. “Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.” Biosens Bioelectron 213 (October 1, 2022): 114445. https://doi.org/10.1016/j.bios.2022.114445.Full Text Link to Item
-
Dinan, Michaela A., Lauren E. Wilson, Melissa A. Greiner, Lisa P. Spees, Jessica E. Pritchard, Tian Zhang, Deborah Kaye, et al. “Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).” Urology 168 (October 2022): 129–36. https://doi.org/10.1016/j.urology.2022.07.012.Full Text Link to Item
-
Spees, Lisa P., Michaela A. Dinan, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.” Clin Genitourin Cancer 20, no. 5 (October 2022): e396–405. https://doi.org/10.1016/j.clgc.2022.04.010.Full Text Link to Item
-
George, Daniel J., David R. Spigel, Lucio N. Gordan, Samith T. Kochuparambil, Ana M. Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, et al. “Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.” Bmj Open 12, no. 9 (September 14, 2022): e058396. https://doi.org/10.1136/bmjopen-2021-058396.Full Text Link to Item
-
Chowdhury-Paulino, Ilkania M., Caroline Ericsson, Randy Vince, Daniel E. Spratt, Daniel J. George, and Lorelei A. Mucci. “Racial disparities in prostate cancer among black men: epidemiology and outcomes.” Prostate Cancer Prostatic Dis 25, no. 3 (September 2022): 397–402. https://doi.org/10.1038/s41391-021-00451-z.Full Text Link to Item
-
George, Daniel J., Krishnan Ramaswamy, Ahong Huang, David Russell, Jack Mardekian, Neil M. Schultz, Nora Janjan, and Stephen J. Freedland. “Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.” Prostate Cancer and Prostatic Diseases 25, no. 3 (September 2022): 524–30. https://doi.org/10.1038/s41391-021-00463-9.Full Text
-
Michael, Zoe D., Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, et al. “Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.” World J Mens Health, August 16, 2022. https://doi.org/10.5534/wjmh.220068.Full Text Link to Item
-
Chen, Yu-Wei, Matthew D. Tucker, Landon C. Brown, Hesham A. Yasin, Kristin K. Ancell, Andrew J. Armstrong, Kathryn E. Beckermann, et al. “The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.” Cancers 14, no. 15 (August 2022): 3830. https://doi.org/10.3390/cancers14153830.Full Text
-
George, D. J. “Divide and Conquer, Cancer.” Clinical Advances in Hematology and Oncology 20, no. 7 (July 1, 2022): 407.
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).” Clin Cancer Res 28, no. 13 (July 1, 2022): 2771–78. https://doi.org/10.1158/1078-0432.CCR-21-2386.Full Text Link to Item
-
Kaye, Deborah R., Lauren E. Wilson, Melissa A. Greiner, Lisa P. Spees, Jessica E. Pritchard, Tian Zhang, Craig E. Pollack, et al. “Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.” J Geriatr Oncol 13, no. 5 (June 2022): 614–23. https://doi.org/10.1016/j.jgo.2022.01.008.Full Text Link to Item
-
Labriola, Matthew K., and Daniel J. George. “Setting a new standard for long-term survival in metastatic kidney cancer.” Cancer 128, no. 11 (June 1, 2022): 2058–60. https://doi.org/10.1002/cncr.34177.Full Text Link to Item
-
Torres, Aracelis Z., Nathan C. Nussbaum, Christina M. Parrinello, Ariel B. Bourla, Bryan E. Bowser, Samuel Wagner, David C. Tabano, Daniel George, and Rebecca A. Miksad. “Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.” Adv Ther 39, no. 6 (June 2022): 2831–49. https://doi.org/10.1007/s12325-022-02091-8.Full Text Link to Item
-
Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, et al. “Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.” Prostate 82, no. 7 (May 2022): 858–66. https://doi.org/10.1002/pros.24329.Full Text Link to Item
-
Brown, Landon C., Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, et al. “A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 762–69. https://doi.org/10.1038/s41391-022-00524-7.Full Text Link to Item
-
Tagawa, Scott T., Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, and Daniel J. George. “Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 800–801. https://doi.org/10.1038/s41391-021-00401-9.Full Text Link to Item
-
Zheng, Jia, Fanny Sampurno, Daniel J. George, Alicia K. Morgans, Hannah Nguyen, Janet L. Abrahm, Anders Bjartell, et al. “Establishing metastatic prostate cancer quality indicators using a modified Delphi approach.” Clin Genitourin Cancer 20, no. 2 (April 2022): e151–57. https://doi.org/10.1016/j.clgc.2021.11.018.Full Text Link to Item
-
Emamekhoo, Hamid, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.” Cancer 128, no. 5 (March 1, 2022): 966–74. https://doi.org/10.1002/cncr.34016.Full Text Link to Item
-
Harrison, Michael R., Paul G. Davis, Michel G. Khouri, David B. Bartlett, Rajan T. Gupta, Andrew J. Armstrong, Megan A. McNamara, et al. “A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).” Prostate Cancer Prostatic Dis 25, no. 1 (March 2022): 58–64. https://doi.org/10.1038/s41391-022-00519-4.Full Text Link to Item
-
Smith, Matthew R., Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, et al. “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.” Lancet Oncol 23, no. 3 (March 2022): 362–73. https://doi.org/10.1016/S1470-2045(21)00757-9.Full Text Link to Item
-
Costello, Brian A., Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka Vaishampayan, Heather Jim, Mayer N. Fishman, et al. “A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.” Clin Genitourin Cancer 20, no. 1 (February 2022): 1–10. https://doi.org/10.1016/j.clgc.2021.07.002.Full Text Link to Item
-
George, Daniel J., Neeraj Agarwal, Oliver Sartor, Cora N. Sternberg, Bertrand Tombal, Fred Saad, Kurt Miller, et al. “Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).” Prostate Cancer Prostatic Dis 25, no. 2 (February 2022): 306–13. https://doi.org/10.1038/s41391-021-00488-0.Full Text Link to Item
-
Mahal, Brandon A., Travis Gerke, Shivanshu Awasthi, Howard R. Soule, Jonathan W. Simons, Andrea Miyahira, Susan Halabi, et al. “Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.” Eur Urol Oncol 5, no. 1 (February 2022): 18–29. https://doi.org/10.1016/j.euo.2021.07.006.Full Text Link to Item
-
Tykodi, Scott S., Lucio N. Gordan, Robert S. Alter, Edward Arrowsmith, Michael R. Harrison, Ivor Percent, Rakesh Singal, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.” J Immunother Cancer 10, no. 2 (February 2022). https://doi.org/10.1136/jitc-2021-003844.Full Text Link to Item
-
Xu, Lingfan, Bing Zhao, William Butler, Huan Xu, Nan Song, Xufeng Chen, J. Spencer Hauck, et al. “Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.” Oncogene 41, no. 8 (February 2022): 1140–54. https://doi.org/10.1038/s41388-021-02155-z.Full Text Link to Item
-
O’Sullivan, Joe M., Rana R. McKay, Kambiz Rahbar, Karim Fizazi, Daniel J. George, Bertrand Tombal, Anja Schmall, Per Sandström, Frank Verholen, and Neal Shore. “Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.” Front Med (Lausanne) 9 (2022). https://doi.org/10.3389/fmed.2022.1070392.Full Text Link to Item
-
Sartor, Oliver, Daniel George, Bertrand Tombal, Neeraj Agarwal, Celestia S. Higano, Cora N. Sternberg, Kurt Miller, et al. “Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.” Future Oncol 18, no. 1 (January 2022): 35–45. https://doi.org/10.2217/fon-2021-0886.Full Text Link to Item
-
Hahn, Andrew W., Daniel J. George, and Neeraj Agarwal. “An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.” Clin Cancer Res 27, no. 24 (December 15, 2021): 6619–21. https://doi.org/10.1158/1078-0432.CCR-21-3029.Full Text Link to Item
-
Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, et al. “Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.” Eur Urol Open Sci 34 (December 2021): 70–78. https://doi.org/10.1016/j.euros.2021.09.015.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol 4, no. 6 (December 2021): 948–54. https://doi.org/10.1016/j.euo.2020.01.005.Full Text Link to Item
-
Tagawa, Scott T., Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, and Daniel J. George. “Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis 24, no. 4 (December 2021): 1032–40. https://doi.org/10.1038/s41391-021-00318-3.Full Text Link to Item
-
Wheeler, Stephanie B., Lisa P. Spees, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.” Jco Oncol Pract 17, no. 12 (December 2021): e1895–1904. https://doi.org/10.1200/OP.20.01082.Full Text Link to Item
-
Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.Full Text Link to Item
-
George, Daniel J., and David P. Dearnaley. “Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.” Future Oncol 17, no. 33 (November 2021): 4431–46. https://doi.org/10.2217/fon-2021-0575.Full Text Link to Item
-
Rose, Tracy L., Michael R. Harrison, Allison M. Deal, Sundhar Ramalingam, Young E. Whang, Blaine Brower, Mary Dunn, et al. “Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.” J Clin Oncol 39, no. 28 (October 1, 2021): 3140–48. https://doi.org/10.1200/JCO.21.01003.Full Text Link to Item
-
Spees, Lisa P., Stephanie B. Wheeler, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.” Cancer Med 10, no. 19 (October 2021): 6653–65. https://doi.org/10.1002/cam4.4201.Full Text Link to Item
-
Powles, Thomas, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, et al. “Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.” Bmc Cancer 21, no. 1 (September 15, 2021): 1023. https://doi.org/10.1186/s12885-021-08693-9.Full Text Link to Item
-
Brown, Landon C., Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe C. Ornstein, and Tian Zhang. “Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.” J Immunother Cancer 9, no. 9 (September 2021). https://doi.org/10.1136/jitc-2021-003281.Full Text Link to Item
-
George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.Full Text Link to Item
-
Brown, Landon C., Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, et al. “Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.” Clin Cancer Res 27, no. 14 (July 15, 2021): 4077–88. https://doi.org/10.1158/1078-0432.CCR-20-3471.Full Text Link to Item
-
Harrison, Michael R., Brian A. Costello, Nrupen A. Bhavsar, Ulka Vaishampayan, Sumanta K. Pal, Yousef Zakharia, Heather S. L. Jim, et al. “Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).” Cancer 127, no. 13 (July 1, 2021): 2204–12. https://doi.org/10.1002/cncr.33494.Full Text Open Access Copy Link to Item
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3317–28. https://doi.org/10.1158/1078-0432.CCR-20-4504.Full Text Link to Item
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3503. https://doi.org/10.1158/1078-0432.CCR-21-1636.Full Text Link to Item
-
Scher, H. I., A. J. Armstrong, J. D. Schonhoft, A. Gill, J. L. Zhao, E. Barnett, E. Carbone, et al. “Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.” Eur J Cancer 150 (June 2021): 83–94. https://doi.org/10.1016/j.ejca.2021.02.042.Full Text Link to Item
-
Al Abo, Muthana, Terry Hyslop, Xiaodi Qin, Kouros Owzar, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.” Genomics 113, no. 3 (May 2021): 1234–46. https://doi.org/10.1016/j.ygeno.2021.02.020.Full Text Link to Item
-
Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.Full Text Link to Item
-
Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.Full Text Link to Item
-
McKay, Rana R., Theresa Gold, Jelani C. Zarif, Ilkania M. Chowdhury-Paulino, Adam Friedant, Travis Gerke, Marie Grant, et al. “Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.” Jco Glob Oncol 7 (April 2021): 495–505. https://doi.org/10.1200/GO.20.00571.Full Text Link to Item
-
Smith, Sonali M., Kerri Wachter, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa L. Johnson, et al. “Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.” J Clin Oncol 39, no. 10 (April 1, 2021): 1165–84. https://doi.org/10.1200/JCO.20.03420.Full Text Link to Item
-
Zhang, Tian, and Daniel J. George. “Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.” Nat Med 27, no. 4 (April 2021): 586–88. https://doi.org/10.1038/s41591-021-01320-x.Full Text Link to Item
-
Xu, Lingfan, Yu Yin, Yanjing Li, Xufeng Chen, Yan Chang, Hong Zhang, Juan Liu, et al. “A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.” Proc Natl Acad Sci U S A 118, no. 13 (March 30, 2021). https://doi.org/10.1073/pnas.2012748118.Full Text Link to Item
-
Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.Full Text Open Access Copy Link to Item
-
Casey, Michelle, Evgeny Degtyarev, María José Lechuga, Paola Aimone, Alain Ravaud, Robert J. Motzer, Feng Liu, et al. “Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.” Pharm Stat 20, no. 2 (March 2021): 324–34. https://doi.org/10.1002/pst.2079.Full Text Link to Item
-
Hong, C., K. A. Batich, G. Almquist, L. Villa, D. J. George, and T. Zhang. “Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy.” Current Problems in Cancer: Case Reports 3 (March 1, 2021). https://doi.org/10.1016/j.cpccr.2021.100060.Full Text
-
Kao, Chester, Daniel J. George, and Tian Zhang. “An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).” Oncologist 26, no. 3 (March 2021): e508–11. https://doi.org/10.1002/onco.13617.Full Text Link to Item
-
Pal, Sumanta K., Catherine Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y. C. Heng, Brian Shuch, et al. “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.” Lancet 397, no. 10275 (February 20, 2021): 695–703. https://doi.org/10.1016/S0140-6736(21)00152-5.Full Text Link to Item
-
Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14. https://doi.org/10.1186/s40364-021-00267-y.Full Text Link to Item
-
Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.” Future Oncol 17, no. 4 (February 2021): 403–9. https://doi.org/10.2217/fon-2020-0652.Full Text Link to Item
-
George, Daniel J., Chung-Han Lee, and Daniel Heng. “New approaches to first-line treatment of advanced renal cell carcinoma.” Ther Adv Med Oncol 13 (2021): 17588359211034708. https://doi.org/10.1177/17588359211034708.Full Text Link to Item
-
Wilson, Lauren E., Lisa Spees, Jessica Pritchard, Melissa A. Greiner, Charles D. Scales, Christopher D. Baggett, Deborah Kaye, et al. “Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.” Kidney Cancer 5, no. 3 (2021): 115–27. https://doi.org/10.3233/KCA-210119.Full Text Link to Item
-
Chen, Ronald C., Toni K. Choueiri, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Aaron D. Falchook, Michael J. Morris, Daniel J. George, and Darren R. Feldman. “Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).” Cancer 126, no. 24 (December 15, 2020): 5311–18. https://doi.org/10.1002/cncr.33169.Full Text Link to Item
-
Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.Full Text Link to Item
-
Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 23, no. 4 (December 2020): 680–88. https://doi.org/10.1038/s41391-020-0236-0.Full Text Link to Item
-
Szymaniak, Brittany M., Lauren A. Facchini, Veda N. Giri, Emmanuel S. Antonarakis, Tomasz M. Beer, Maria I. Carlo, Daniel C. Danila, et al. “Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.” Jco Oncol Pract 16, no. 12 (December 2020): 811–19. https://doi.org/10.1200/OP.20.00431.Full Text Link to Item
-
Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.Full Text Link to Item
-
Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.Full Text Open Access Copy Link to Item
-
Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.” Clin Cancer Res 26, no. 18 (September 15, 2020): 4863–68. https://doi.org/10.1158/1078-0432.CCR-20-0704.Full Text Link to Item
-
Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.Full Text Link to Item
-
George, Daniel J., Oliver Sartor, Kurt Miller, Fred Saad, Bertrand Tombal, Ján Kalinovský, Xiaolong Jiao, Krishna Tangirala, Cora N. Sternberg, and Celestia S. Higano. “Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.” Clin Genitourin Cancer 18, no. 4 (August 2020): 284–94. https://doi.org/10.1016/j.clgc.2019.12.019.Full Text Link to Item
-
Bitting, Rhonda L., Michael Goodman, and Daniel J. George. “Racial Disparity in Response to Prostate Cancer Systemic Therapies.” Curr Oncol Rep 22, no. 9 (July 23, 2020): 96. https://doi.org/10.1007/s11912-020-00966-z.Full Text Link to Item
-
Rencsok, Emily M., Latifa A. Bazzi, Rana R. McKay, Franklin W. Huang, Adam Friedant, Jake Vinson, Samuel Peisch, et al. “Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.” Cancer Epidemiol Biomarkers Prev 29, no. 7 (July 2020): 1374–80. https://doi.org/10.1158/1055-9965.EPI-19-1616.Full Text Link to Item
-
Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.Full Text Link to Item
-
Shore, Neal D., Fred Saad, Michael S. Cookson, Daniel J. George, Daniel R. Saltzstein, Ronald Tutrone, Hideyuki Akaza, et al. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” N Engl J Med 382, no. 23 (June 4, 2020): 2187–96. https://doi.org/10.1056/NEJMoa2004325.Full Text Link to Item
-
Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.Full Text Link to Item
-
Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, and Daniel J. George. “Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.” Adv Ther 37, no. 5 (May 2020): 2083–97. https://doi.org/10.1007/s12325-020-01260-x.Full Text Link to Item
-
Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.Full Text Link to Item
-
Markham, Merry Jennifer, Kerri Wachter, Neeraj Agarwal, Monica M. Bertagnolli, Susan Marina Chang, William Dale, Catherine S. M. Diefenbach, et al. “Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” J Clin Oncol 38, no. 10 (April 1, 2020): 1081. https://doi.org/10.1200/JCO.19.03141.Full Text Link to Item
-
George, D. J. “What can we learn from cancer disparities?” Gastroenterology and Hepatology 16, no. 3 (March 1, 2020): 134.
-
George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.Full Text Link to Item
-
Labriola, Matthew Kyle, Jason Zhu, Rajan T. Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.Full Text Link to Item
-
Wood, Sarah Yenser, Joanne C. Ryan, Andrew G. Clair, and Daniel J. George. “Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.” Future Oncol 16, no. 4 (February 2020): 39–47. https://doi.org/10.2217/fon-2019-0369.Full Text Link to Item
-
Kinsey, Emily N., and Daniel George. “Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy.” Eur Urol Focus 6, no. 1 (January 15, 2020): 9–10. https://doi.org/10.1016/j.euf.2019.05.013.Full Text Link to Item
-
Armstrong, Andrew J., Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Patrick Healy, et al. “Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.” Jco Precis Oncol 4 (2020). https://doi.org/10.1200/PO.20.00200.Full Text Link to Item
-
Brown, Landon C., Tian Zhang, and Daniel J. George. “The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.” Cancer J 26, no. 5 (2020): 376–81. https://doi.org/10.1097/PPO.0000000000000469.Full Text Link to Item
-
Zhang, Tian, Joyce K. Hwang, Daniel J. George, and Sumanta K. Pal. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.” Cancer Treat Res Commun 24 (2020): 100183. https://doi.org/10.1016/j.ctarc.2020.100183.Full Text Link to Item
-
Rini, Brian I., Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, et al. “The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).” J Immunother Cancer 7, no. 1 (December 20, 2019): 354. https://doi.org/10.1186/s40425-019-0813-8.Full Text Link to Item
-
Holl, Eda K., Megan A. McNamara, Patrick Healy, Monika Anand, Raoul S. Concepcion, Coleman D. Breland, Igor Dumbudze, et al. “Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 588–92. https://doi.org/10.1038/s41391-019-0144-3.Full Text Link to Item
-
George, Daniel J., Colin Hessel, Susan Halabi, M Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, et al. “Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.” Oncologist 24, no. 11 (November 2019): 1497–1501. https://doi.org/10.1634/theoncologist.2019-0316.Full Text Link to Item
-
George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.Full Text Link to Item
-
Zhu, Jason, Matthew Tucker, Daniele Marin, Rajan T. Gupta, Patrick Healy, Michael Humeniuk, Casey Jarvis, et al. “Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.” Urol Oncol 37, no. 11 (November 2019): 813.e1-813.e9. https://doi.org/10.1016/j.urolonc.2019.06.015.Full Text Link to Item
-
Flaifel, Abdallah, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, et al. “PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.” Clin Cancer Res 25, no. 20 (October 15, 2019): 6080–88. https://doi.org/10.1158/1078-0432.CCR-19-1135.Full Text Link to Item
-
Freedland, Stephen J., Lauren Howard, Jenifer Allen, Jordan Smith, Jennifer Stout, William Aronson, Brant A. Inman, et al. “A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.” Prostate Cancer Prostatic Dis 22, no. 3 (September 2019): 428–37. https://doi.org/10.1038/s41391-019-0126-5.Full Text Open Access Copy Link to Item
-
Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Howard I. Scher, Emmanuel S. Antonarakis, and Daniel J. George. “Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.” J Clin Oncol 37, no. 24 (August 20, 2019): 2184–86. https://doi.org/10.1200/JCO.19.01230.Full Text Link to Item
-
Griffith, Sandra D., Rebecca A. Miksad, Geoff Calkins, Paul You, Nicole G. Lipitz, Ariel B. Bourla, Erin Williams, et al. “Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.” Jco Clin Cancer Inform 3 (August 2019): 1–13. https://doi.org/10.1200/CCI.19.00013.Full Text Link to Item
-
Paller, Channing J., Emmanuel S. Antonarakis, Tomasz M. Beer, Hala T. Borno, Maria I. Carlo, Daniel J. George, Julie N. Graff, et al. “Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.” Clinical Genitourinary Cancer 17, no. 4 (August 2019): 275-282.e1. https://doi.org/10.1016/j.clgc.2019.04.013.Full Text
-
Tucker, Matthew D., Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, et al. “Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.” Cancer Med 8, no. 10 (August 2019): 4644–55. https://doi.org/10.1002/cam4.2375.Full Text Link to Item
-
George, D. J. “Caring for every patient, learning from every patient.” Clinical Advances in Hematology and Oncology 17, no. 7 (July 1, 2019): 364.
-
George, Daniel J. “Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.” Clin Adv Hematol Oncol 17, no. 7 (July 2019): 382–85.Link to Item
-
McNamara, Megan Ann, Taofik Oyekunle, Bennett B. Chin, Jorge Oldan, Aseem Anand, Michala Ritz, Lindsey Shantzer, Monika Anand, Andrew J. Armstrong, and Daniel J. George. “Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.” Prostate 79, no. 10 (July 2019): 1106–16. https://doi.org/10.1002/pros.23822.Full Text Link to Item
-
Pal, Sumanta, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, and Daniel George. “Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.” Bmc Cancer 19, no. 1 (June 7, 2019): 548. https://doi.org/10.1186/s12885-019-5716-z.Full Text Link to Item
-
Heath, Elisabeth I., David M. Nanus, Susan Slovin, Chuck Strand, Celestia Higano, Virgil H. Simons, Crawford Johnson, et al. “Prostate Cancer National Summit's Call to Action.” Clin Genitourin Cancer 17, no. 3 (June 2019): 161–68. https://doi.org/10.1016/j.clgc.2019.04.002.Full Text Link to Item
-
Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.Full Text Link to Item
-
Robinson, Timothy J., Jennifer A. Freedman, Muthana Al Abo, April E. Deveaux, Bonnie LaCroix, Brendon M. Patierno, Daniel J. George, and Steven R. Patierno. “Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities.” Clin Cancer Res 25, no. 10 (May 15, 2019): 2963–68. https://doi.org/10.1158/1078-0432.CCR-18-2445.Full Text Link to Item
-
George, D. J. “Outcomes.” Clinical Advances in Hematology and Oncology 17, no. 5 (May 1, 2019): 258.
-
Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.Full Text Link to Item
-
George, Daniel J. “Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary.” Clin Adv Hematol Oncol 17 Suppl 8, no. 4 (April 2019): 17–19.Link to Item
-
Den, Robert B., Daniel George, Christopher Pieczonka, and Megan McNamara. “Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.” Am J Clin Oncol 42, no. 4 (April 2019): 399–406. https://doi.org/10.1097/COC.0000000000000528.Full Text Link to Item
-
George, D. J. “Talk to me.” Clinical Advances in Hematology and Oncology 17, no. 3 (March 1, 2019): 142.
-
George, Daniel J., Jean-Francois Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, et al. “Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.” Clin Cancer Res 25, no. 4 (February 15, 2019): 1165–73. https://doi.org/10.1158/1078-0432.CCR-18-1724.Full Text Link to Item
-
Halabi, Susan, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson, Kim N. Chi, et al. “Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.” J Clin Oncol 37, no. 5 (February 10, 2019): 403–10. https://doi.org/10.1200/JCO.18.01279.Full Text Link to Item
-
Zhang, Tian, Daniel J. George, and Andrew J. Armstrong. “Precision Medicine Approaches When Prostate Cancer Akts Up.” Clin Cancer Res 25, no. 3 (February 1, 2019): 901–3. https://doi.org/10.1158/1078-0432.CCR-18-2491.Full Text Link to Item
-
Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.” J Immunother Cancer 7, no. 1 (January 24, 2019): 18. https://doi.org/10.1186/s40425-018-0489-5.Full Text Link to Item
-
George, D. J. “Clinical advances: Past and present.” Clinical Advances in Hematology and Oncology 17, no. 1 (January 1, 2019): 6.
-
Ramalingam, S., M. Walker, D. J. George, and M. R. Harrison. “Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival.” Kidney Cancer 3, no. 2 (January 1, 2019): 133–40. https://doi.org/10.3233/KCA-190059.Full Text
-
Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R. Zalutsky, Charles Spritzer, et al. “Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.” Plos One 14, no. 5 (2019): e0216934. https://doi.org/10.1371/journal.pone.0216934.Full Text Link to Item
-
Bergerot, Cristiane Decat, Dena Battle, Paulo Gustavo Bergerot, Nazli Dizman, Eric Jonasch, Hans J. Hammers, Daniel J. George, et al. “Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.” Front Oncol 9 (2019): 11. https://doi.org/10.3389/fonc.2019.00011.Full Text Link to Item
-
Staehler, Michael, Dena Battle, Axel Bex, Hans Hammers, and Daniel George. “Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.” Eur Urol 74, no. 6 (December 2018): 842–43. https://doi.org/10.1016/j.eururo.2018.08.011.Full Text Link to Item
-
Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies.” Precis Clin Med 1, no. 3 (December 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.Full Text Link to Item
-
Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].” Eur J Cancer 103 (November 2018): 287. https://doi.org/10.1016/j.ejca.2018.09.022.Full Text Link to Item
-
Rini, Brian I., Harold J. Burstein, and Daniel J. George. “Information Transparency in the Drug Approval Process.” Jama Oncol 4, no. 11 (November 1, 2018): 1621–22. https://doi.org/10.1001/jamaoncol.2018.4143.Full Text Link to Item
-
Gao, Xin, Opeyemi Jegede, Connor Gray, Paul J. Catalano, Jesse Novak, David J. Kwiatkowski, Rana R. McKay, et al. “Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.” Clin Genitourin Cancer 16, no. 5 (October 2018): 341–48. https://doi.org/10.1016/j.clgc.2018.04.001.Full Text Link to Item
-
Staehler, M., R. J. Motzer, D. J. George, H. S. Pandha, F. Donskov, B. Escudier, A. J. Pantuck, et al. “Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.” Ann Oncol 29, no. 10 (October 1, 2018): 2098–2104. https://doi.org/10.1093/annonc/mdy329.Full Text Link to Item
-
Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.” Angew Chem Int Ed Engl 57, no. 39 (September 24, 2018): 12780–84. https://doi.org/10.1002/anie.201807582.Full Text Link to Item
-
Powles, Thomas, Robert J. Motzer, Bernard Escudier, Sumanta Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, et al. “Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.” Br J Cancer 119, no. 6 (September 2018): 663–69. https://doi.org/10.1038/s41416-018-0164-0.Full Text Link to Item
-
Freedman, Jennifer A., Yanru Wang, Xuechan Li, Hongliang Liu, Patricia G. Moorman, Daniel J. George, Norman H. Lee, Terry Hyslop, Qingyi Wei, and Steven R. Patierno. “Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.” Carcinogenesis 39, no. 7 (July 3, 2018): 879–88. https://doi.org/10.1093/carcin/bgy062.Full Text Open Access Copy Link to Item
-
Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.” Clin Genitourin Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.Full Text Link to Item
-
Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.” Eur J Cancer 94 (May 2018): 115–25. https://doi.org/10.1016/j.ejca.2018.02.012.Full Text Link to Item
-
Slovin, Susan, William Clark, Joan Carles, Andrew Krivoshik, Jung Wook Park, Fong Wang, and Daniel George. “Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.” Jama Oncol 4, no. 5 (May 1, 2018): 702–6. https://doi.org/10.1001/jamaoncol.2017.3361.Full Text Link to Item
-
George, Daniel J., Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, et al. “Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.” Clin Cancer Res 24, no. 7 (April 1, 2018): 1554–61. https://doi.org/10.1158/1078-0432.CCR-17-2822.Full Text Link to Item
-
Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?” Prostate Cancer Prostatic Dis 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.Full Text Link to Item
-
Ramalingam, Sundhar, Daniel J. George, and Michael R. Harrison. “How we treat brain metastases in metastatic renal cell carcinoma.” Clin Adv Hematol Oncol 16, no. 2 (February 2018): 110–14.Link to Item
-
Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.Full Text Link to Item
-
Koshkin, Vadim S., Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, et al. “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.” J Immunother Cancer 6, no. 1 (January 29, 2018): 9. https://doi.org/10.1186/s40425-018-0319-9.Full Text Open Access Copy Link to Item
-
Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.” J Immunother Cancer 6, no. 1 (January 25, 2018): 4. https://doi.org/10.1186/s40425-018-0314-1.Full Text Open Access Copy Link to Item
-
Armstrong, A. J., E. S. Antonarakis, M. -. E. Taplin, W. K. Kelly, H. Beltran, K. Fizazi, W. L. Dahut, et al. “Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.” Ann Oncol 29, no. 1 (January 1, 2018): 23–25. https://doi.org/10.1093/annonc/mdx648.Full Text Link to Item
-
Carlo, Maria I., Veda N. Giri, Channing J. Paller, Wassim Abida, Joshi J. Alumkal, Tomasz M. Beer, Himisha Beltran, et al. “Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.” Jco Precis Oncol 2018 (2018). https://doi.org/10.1200/PO.18.00060.Full Text Link to Item
-
Motzer, Robert J., Alain Ravaud, Jean-Jacques Patard, Hardev S. Pandha, Daniel J. George, Anup Patel, Yen-Hwa Chang, et al. “Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.” Eur Urol 73, no. 1 (January 2018): 62–68. https://doi.org/10.1016/j.eururo.2017.09.008.Full Text Link to Item
-
Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.Full Text Open Access Copy Link to Item
-
George, Daniel J. “Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 15, no. 9 (September 2017): 690–94.Link to Item
-
Wang, Yanru, Jennifer A. Freedman, Hongliang Liu, Patricia G. Moorman, Terry Hyslop, Daniel J. George, Norman H. Lee, Steven R. Patierno, and Qingyi Wei. “Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.” Int J Cancer 141, no. 4 (August 15, 2017): 731–43. https://doi.org/10.1002/ijc.30787.Full Text Link to Item
-
Tang, X., C. -. K. Ding, J. Wu, J. Sjol, S. Wardell, I. Spasojevic, D. George, et al. “Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.” Oncogene 36, no. 30 (July 27, 2017): 4235–42. https://doi.org/10.1038/onc.2016.394.Full Text Link to Item
-
Tang, X., C. -. K. Ding, J. Wu, J. Sjol, S. Wardell, I. Spasojevic, D. George, et al. “Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.” Oncogene 36, no. 30 (July 27, 2017): 4379. https://doi.org/10.1038/onc.2017.192.Full Text Link to Item
-
Harshman, L. C., C. G. Drake, N. B. Haas, J. Manola, M. Puligandla, S. Signoretti, D. Cella, et al. “Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.” Kidney Cancer 1, no. 1 (July 26, 2017): 31–40. https://doi.org/10.3233/KCA-170010.Full Text Link to Item
-
Choueiri, Toni K., Susan Halabi, Michael J. Morris, and Daniel George. “Reply to B. Rini et al and S. Buti et al.” J Clin Oncol 35, no. 16 (June 1, 2017): 1859–60. https://doi.org/10.1200/JCO.2017.72.2629.Full Text Link to Item
-
Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.Full Text Link to Item
-
Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, and Daniel J. George. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.” Cancer Invest 35, no. 5 (May 28, 2017): 333–44. https://doi.org/10.1080/07357907.2017.1289215.Full Text Link to Item
-
Madden-Fuentes, Ramiro Jose, Bridget F. Koontz, Michael R. Harrison, Daniel J. George, Brittany Davidson, Brian F. Gilmore, Judd W. Moul, Christopher Mantyh, and Andrew C. Peterson. “How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?” Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286–94.Link to Item
-
Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies.” Future Oncol 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.Full Text Link to Item
-
Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.Full Text Link to Item
-
STARSurg Collaborative. Electronic address: http://www.starsurg.org/, Adrian F. M., and Adrian F. M. STARSurg Collaborative. “Students' participation in collaborative research should be recognised.” Int J Surg 39 (March 2017): 234–37. https://doi.org/10.1016/j.ijsu.2017.01.114.Full Text Link to Item
-
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, Olwen Hahn, M Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, et al. “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.” J Clin Oncol 35, no. 6 (February 20, 2017): 591–97. https://doi.org/10.1200/JCO.2016.70.7398.Full Text Link to Item
-
Ramalingam, Sundhar, richard Bloomfield, daniel George, zubin Eapen, and M. R. Harrison. “Mobile Health Applications in Patients With Metastatic Renal Cell Carcinoma.” Kidney Cancer Journal 15, no. 4 (2017): 101–5.Open Access Copy Link to Item
-
STARSurg Collaborative, Sina. “Safety of Nonsteroidal Anti-inflammatory Drugs in Major Gastrointestinal Surgery: A Prospective, Multicenter Cohort Study.” World J Surg 41, no. 1 (January 2017): 47–55. https://doi.org/10.1007/s00268-016-3727-3.Full Text Link to Item
-
Ravaud, Alain, Robert J. Motzer, Hardev S. Pandha, Daniel J. George, Allan J. Pantuck, Anup Patel, Yen-Hwa Chang, et al. “Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.” N Engl J Med 375, no. 23 (December 8, 2016): 2246–54. https://doi.org/10.1056/NEJMoa1611406.Full Text Link to Item
-
Milowsky, Matthew I., Matthew D. Galsky, Michael J. Morris, Daniel J. Crona, Daniel J. George, Robert Dreicer, Kin Tse, et al. “Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.” Urol Oncol 34, no. 12 (December 2016): 530.e15-530.e21. https://doi.org/10.1016/j.urolonc.2016.07.005.Full Text Link to Item
-
Holl, Eda K., Michael C. Brown, David Boczkowski, Megan A. McNamara, Daniel J. George, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.” Oncotarget 7, no. 48 (November 29, 2016): 79828–41. https://doi.org/10.18632/oncotarget.12975.Full Text Link to Item
-
Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.” Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.Full Text Link to Item
-
Shao, Zhiying, Andrew Z. Wang, Daniel J. George, and Tian Zhang. “Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.” Asian J Urol 3, no. 4 (October 2016): 268–77. https://doi.org/10.1016/j.ajur.2016.08.013.Full Text Link to Item
-
Hu, Rachel, Daniel J. George, and Tian Zhang. “What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.” Ther Adv Urol 8, no. 4 (August 2016): 272–78. https://doi.org/10.1177/1756287216645314.Full Text Link to Item
-
Gupta, Rajan T., Alison Flanagan Brown, Rachel Kloss Silverman, Kae Jack Tay, John F. Madden, Daniel J. George, and Thomas J. Polascik. “Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?” Ajr Am J Roentgenol 207, no. 1 (July 2016): 87–95. https://doi.org/10.2214/AJR.15.15878.Full Text Link to Item
-
Nussbaum, N., D. J. George, A. P. Abernethy, C. M. Dolan, N. Oestreicher, S. Flanders, and T. B. Dorff. “Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.” Prostate Cancer Prostatic Dis 19, no. 2 (June 2016): 111–21. https://doi.org/10.1038/pcan.2015.42.Full Text Link to Item
-
Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.Full Text Open Access Copy Link to Item
-
Scher, Howard I., Michael J. Morris, Walter M. Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, et al. “Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.” J Clin Oncol 34, no. 12 (April 20, 2016): 1402–18. https://doi.org/10.1200/JCO.2015.64.2702.Full Text Link to Item
-
Tang, Xiaohu, Jianli Wu, Chien-Kuang Ding, Min Lu, Melissa M. Keenan, Chao-Chieh Lin, Chih-An Lin, et al. “Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas.” Cancer Res 76, no. 7 (April 1, 2016): 1892–1903. https://doi.org/10.1158/0008-5472.CAN-15-2328.Full Text Link to Item
-
Armstrong, Andrew J., Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, et al. “Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.” Lancet Oncol 17, no. 3 (March 2016): 378–88. https://doi.org/10.1016/S1470-2045(15)00515-X.Full Text Link to Item
-
Dinan, Michaela A., Yanhong Li, Yinghong Zhang, Suzanne B. Stewart, Lesley H. Curtis, Daniel J. George, and Shelby D. Reed. “Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.” Clin Genitourin Cancer 14, no. 1 (February 2016): 28-37.e2. https://doi.org/10.1016/j.clgc.2015.07.006.Full Text Link to Item
-
Kim, Hyung L., Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, et al. “A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).” Ebiomedicine 2, no. 11 (November 2015): 1814–20. https://doi.org/10.1016/j.ebiom.2015.09.012.Full Text Link to Item
-
Mitchell, Aaron P., Michael R. Harrison, Mark S. Walker, Daniel J. George, Amy P. Abernethy, and Bradford R. Hirsch. “Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.” J Oncol Pract 11, no. 6 (November 2015): 491–97. https://doi.org/10.1200/JOP.2015.004929.Full Text Link to Item
-
Morgans, Alicia K., Annelotte C. M. van Bommel, Caleb Stowell, Janet L. Abrahm, Ethan Basch, Justin E. Bekelman, Donna L. Berry, et al. “Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.” Eur Urol 68, no. 5 (November 2015): 891–98. https://doi.org/10.1016/j.eururo.2015.06.007.Full Text Link to Item
-
George, Daniel J., Chadi Nabhan, Todd DeVries, James B. Whitmore, and Leonard G. Gomella. “Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.” Cancer Immunol Res 3, no. 9 (September 2015): 1063–69. https://doi.org/10.1158/2326-6066.CIR-15-0006.Full Text Link to Item
-
Kanesvaran, Ravindran, Kevin Watt, James D. Turnbull, Andrew J. Armstrong, Michael Cohen Wolkowiez, and Daniel J. George. “A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.” Clin Genitourin Cancer 13, no. 4 (August 2015): 319–27. https://doi.org/10.1016/j.clgc.2014.12.011.Full Text Link to Item
-
Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.Full Text Link to Item
-
Flaherty, Keith T., Judith B. Manola, Michael Pins, David F. McDermott, Michael B. Atkins, Janice J. Dutcher, Daniel J. George, Kim A. Margolin, and Robert S. DiPaola. “BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).” J Clin Oncol 33, no. 21 (July 20, 2015): 2384–91. https://doi.org/10.1200/JCO.2015.60.9727.Full Text Link to Item
-
Morgans, A. K., A. C. M. van Bommel, C. Stowell, J. L. Abrahm, E. Basch, J. E. Bekelman, D. L. Berry, et al. “DEVELOPMENT OF A STANDARDIZED SET OF PATIENT-CENTERED OUTCOMES FOR ADVANCED PROSTATE CANCER: AN INTERNATIONAL EFFORT FOR A UNIFIED APPROACH.” Asia Pacific Journal of Clinical Oncology 11 (July 1, 2015): 29–29.Link to Item
-
George, Daniel J. “The future of kidney cancer treatment.” Clin Adv Hematol Oncol 13, no. 6 (June 2015): 368–71.Link to Item
-
Mitchell, Aaron P., Bradford R. Hirsch, Michael R. Harrison, Amy P. Abernethy, and Daniel J. George. “Deferred systemic therapy in patients with metastatic renal cell carcinoma.” Clin Genitourin Cancer 13, no. 3 (June 2015): e159–66. https://doi.org/10.1016/j.clgc.2014.12.017.Full Text Link to Item
-
Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.” Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.Full Text Link to Item
-
McNamara, Megan A., and Daniel J. George. “Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.” Bmc Cancer 15 (May 7, 2015): 371. https://doi.org/10.1186/s12885-015-1390-y.Full Text Link to Item
-
Infante, Jeffrey R., Ramesh K. Ramanathan, Daniel George, Eugene Tan, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, and Sunil Sharma. “A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).” Cancer Chemother Pharmacol 75, no. 4 (April 2015): 729–37. https://doi.org/10.1007/s00280-015-2681-3.Full Text Link to Item
-
Wong, Michael K., Eric Jonasch, Sumanta K. Pal, James E. Signorovitch, Peggy L. Lin, Xufang Wang, Zhimei Liu, et al. “Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.” Expert Opin Pharmacother 16, no. 6 (April 2015): 805–19. https://doi.org/10.1517/14656566.2015.1020298.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.” Urol Oncol 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.Full Text Link to Item
-
Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.” Expert Opin Pharmacother 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.Full Text Link to Item
-
Basch, Ethan, Karen A. Autio, Matthew R. Smith, Antonia V. Bennett, Aaron L. Weitzman, Christian Scheffold, Christopher Sweeney, et al. “Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.” Eur Urol 67, no. 2 (February 2015): 310–18. https://doi.org/10.1016/j.eururo.2014.02.013.Full Text Link to Item
-
Albiges, Laurence, Toni Choueiri, Bernard Escudier, Matthew Galsky, Dan George, Fabian Hofmann, Thomas Lam, et al. “A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.” Eur Urol 67, no. 1 (January 2015): 100–110. https://doi.org/10.1016/j.eururo.2014.04.006.Full Text Link to Item
-
Stewart, Suzanne B., Judd W. Moul, Thomas J. Polascik, Bridget F. Koontz, Cary N. Robertson, Stephen J. Freedland, Daniel J. George, W Robert Lee, Andrew J. Armstrong, and Lionel L. Bañez. “Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?” Int J Urol 21, no. 12 (December 2014): 1215–19. https://doi.org/10.1111/iju.12561.Full Text Link to Item
-
Signorovitch, James E., Nicholas J. Vogelzang, Sumanta K. Pal, Peggy L. Lin, Daniel J. George, Michael K. Wong, Zhimei Liu, et al. “Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.” Curr Med Res Opin 30, no. 11 (November 2014): 2343–53. https://doi.org/10.1185/03007995.2014.949645.Full Text Link to Item
-
Safi, Rachid, Erik R. Nelson, Satish K. Chitneni, Katherine J. Franz, Daniel J. George, Michael R. Zalutsky, and Donald P. McDonnell. “Copper signaling axis as a target for prostate cancer therapeutics.” Cancer Res 74, no. 20 (October 15, 2014): 5819–31. https://doi.org/10.1158/0008-5472.CAN-13-3527.Full Text Open Access Copy Link to Item
-
Sharma, Sunil, Carolyn D. Britten, Joanne Mortimer, Swarupa Kulkarni, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, and Daniel George. “The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.” Cancer Chemother Pharmacol 74, no. 4 (October 2014): 867–74. https://doi.org/10.1007/s00280-014-2454-4.Full Text Link to Item
-
Sternberg, Cora N., Daniel Castellano, Gedske Daugaard, Lajos Géczi, Sebastien J. Hotte, Paul N. Mainwaring, Fred Saad, et al. “Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.” Lancet Oncol 15, no. 11 (October 2014): 1263–68. https://doi.org/10.1016/S1470-2045(14)70417-6.Full Text Link to Item
-
“Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.” Clin Adv Hematol Oncol 12, no. 9 Suppl 17 (September 2014): 1–21.Link to Item
-
George, D. J. “Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.” Clinical Advances in Hematology and Oncology 12, no. 9 (September 1, 2014): 18–21.
-
Hirsch, Bradford R., Michael R. Harrison, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward Stepanski, and Amy P. Abernethy. “Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.” Med Oncol 31, no. 9 (September 2014): 156. https://doi.org/10.1007/s12032-014-0156-8.Full Text Link to Item
-
Hussain, Maha, Paul G. Corn, M Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, et al. “Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.” Clin Cancer Res 20, no. 16 (August 15, 2014): 4218–27. https://doi.org/10.1158/1078-0432.CCR-14-0356.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.Full Text Link to Item
-
Kakkar, Ajay K., Giancarlo Agnelli, William Fisher, Daniel George, Michael R. Lassen, Patrick Mismetti, Patrick Mouret, et al. “Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.” Ann Surg 259, no. 6 (June 2014): 1073–79. https://doi.org/10.1097/SLA.0000000000000430.Full Text Link to Item
-
Younis, Islam R., Daniel J. George, Terence J. McManus, Herbert Hurwitz, Patricia Creel, Andrew J. Armstrong, Jing Jie Yu, et al. “Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.” Cancer Chemother Pharmacol 73, no. 5 (May 2014): 991–97. https://doi.org/10.1007/s00280-014-2432-x.Full Text Link to Item
-
George, Daniel J. “Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary.” Clin Adv Hematol Oncol 12, no. 4 Suppl 11 (April 2014): 12–16.Link to Item
-
Wong, Michael K., Hongbo Yang, James E. Signorovitch, Xufang Wang, Zhimei Liu, Nathan S. Liu, Cynthia Z. Qi, and Daniel J. George. “Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.” Curr Med Res Opin 30, no. 4 (April 2014): 537–45. https://doi.org/10.1185/03007995.2013.871243.Full Text Link to Item
-
Harrison, Michael R., Bradford R. Hirsch, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward Stepanski, and Amy P. Abernethy. “Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.” J Oncol Pract 10, no. 2 (March 2014): e63–72. https://doi.org/10.1200/JOP.2013.001180.Full Text Link to Item
-
Hirsch, Bradford R., Daniel J. George, and Michael R. Harrison. “Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?” Clin Adv Hematol Oncol 12, no. 3 (March 2014): 163–71.Link to Item
-
George, D. J. “Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.” Clinical Advances in Hematology and Oncology 12, no. 9 (January 1, 2014): 18–21.
-
Rampersaud, Edward N., Tobias Klatte, Geoffrey Bass, Jean-Jacques Patard, Karim Bensaleh, Malte Böhm, Ernst P. Allhoff, et al. “The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.” Urol Oncol 32, no. 1 (January 2014): 30.e9-30.13. https://doi.org/10.1016/j.urolonc.2012.10.012.Full Text Link to Item
-
Harrison, Michael R., Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Donald T. Kirkendall, Edward J. Stepanski, and Amy P. Abernethy. “"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.” Clin Genitourin Cancer 11, no. 4 (December 2013): 441–50. https://doi.org/10.1016/j.clgc.2013.05.002.Full Text Link to Item
-
Spritzer, Charles E., P Diana Afonso, Emily N. Vinson, James D. Turnbull, Karla K. Morris, Adam Foye, John F. Madden, Kingshuk Roy Choudhury, Phillip G. Febbo, and Daniel J. George. “Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.” Radiology 269, no. 3 (December 2013): 816–23. https://doi.org/10.1148/radiol.13121782.Full Text Link to Item
-
Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” Clin Genitourin Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.Full Text Link to Item
-
Meadows, Kellen L., Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, and Herbert I. Hurwitz. “Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.” Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C61–C61. https://doi.org/10.1158/1535-7163.targ-13-c61.Full Text
-
Aggarwal, Rahul, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, et al. “The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).” Cancer 119, no. 20 (October 15, 2013): 3636–43. https://doi.org/10.1002/cncr.28285.Full Text Link to Item
-
Peppercorn, Jeffrey, Andrew Armstrong, David W. Zaas, and Daniel George. “Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.” Urol Oncol 31, no. 7 (October 2013): 1079–84. https://doi.org/10.1016/j.urolonc.2011.12.022.Full Text Link to Item
-
Autio, Karen A., Antonia V. Bennett, Xiaoyu Jia, Michael Fruscione, Tomasz M. Beer, Daniel J. George, Michael A. Carducci, et al. “Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.” J Oncol Pract 9, no. 5 (September 2013): 223–29. https://doi.org/10.1200/JOP.2013.000876.Full Text Link to Item
-
George, Daniel J., Andrew J. Armstrong, and Michael R. Harrison. “Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary.” Clin Adv Hematol Oncol 11 Suppl 14, no. 9 (September 2013): 16–22.Link to Item
-
Tewari, Alok K., and Daniel J. George. “Novel chemotherapies in development for management of castration-resistant prostate cancer.” Curr Opin Urol 23, no. 3 (May 2013): 220–29. https://doi.org/10.1097/MOU.0b013e32835f7da2.Full Text Link to Item
-
Inman, Brant A., Michael R. Harrison, and Daniel J. George. “Novel immunotherapeutic strategies in development for renal cell carcinoma.” Eur Urol 63, no. 5 (May 2013): 881–89. https://doi.org/10.1016/j.eururo.2012.10.006.Full Text Link to Item
-
Fisher, W. D., G. Agnelli, D. J. George, A. K. Kakkar, M. R. Lassen, P. Mismetti, P. Mouret, and A. G. G. Turpie. “Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.” Bone Joint J 95-B, no. 4 (April 2013): 459–66. https://doi.org/10.1302/0301-620X.95B4.30730.Full Text Link to Item
-
George, Daniel J. “Recent advances in the management of castration-resistant prostate cancer.” Clin Adv Hematol Oncol 11, no. 3 (March 2013): 181–83.Link to Item
-
Turnbull, James D., Julien Cobert, Tracy Jaffe, Michael R. Harrison, Daniel J. George, and Andrew J. Armstrong. “Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.” Clin Genitourin Cancer 11, no. 1 (March 2013): 45–50. https://doi.org/10.1016/j.clgc.2012.06.001.Full Text Link to Item
-
Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al.” J Clin Oncol 31, no. 7 (March 1, 2013): 972–73. https://doi.org/10.1200/JCO.2012.47.7224.Full Text Link to Item
-
Ryan, Charles J., Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, et al. “Abiraterone in metastatic prostate cancer without previous chemotherapy.” N Engl J Med 368, no. 2 (January 10, 2013): 138–48. https://doi.org/10.1056/NEJMoa1209096.Full Text Link to Item
-
Harrison, Michael R., Terence Z. Wong, Andrew J. Armstrong, and Daniel J. George. “Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.” Cancer Manag Res 5 (2013): 1–14. https://doi.org/10.2147/CMAR.S25537.Full Text Link to Item
-
Roth, Bruce J., Lada Krilov, Sylvia Adams, Carol A. Aghajanian, Peter Bach, Fadi Braiteh, Marcia S. Brose, et al. “Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.” J Clin Oncol 31, no. 1 (January 1, 2013): 131–61. https://doi.org/10.1200/JCO.2012.47.1938.Full Text Link to Item
-
Whang, Young E., Andrew J. Armstrong, W Kimryn Rathmell, Paul A. Godley, William Y. Kim, Raj S. Pruthi, Eric M. Wallen, et al. “A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.” Urol Oncol 31, no. 1 (January 2013): 82–86. https://doi.org/10.1016/j.urolonc.2010.09.018.Full Text Link to Item
-
Sternberg, Cora N., Joaquim Bellmunt, Guru Sonpavde, Arlene O. Siefker-Radtke, Walter M. Stadler, Dean F. Bajorin, Robert Dreicer, et al. “ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.” Eur Urol 63, no. 1 (January 2013): 58–66. https://doi.org/10.1016/j.eururo.2012.08.010.Full Text Link to Item
-
Roe, Matthew T., Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, et al. “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.” N Engl J Med 367, no. 14 (October 4, 2012): 1297–1309. https://doi.org/10.1056/NEJMoa1205512.Full Text Link to Item
-
Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.” J Clin Oncol 30, no. 27 (September 20, 2012): 3402–7. https://doi.org/10.1200/JCO.2011.40.9631.Full Text Link to Item
-
Hirsch, B. R., and D. J. George. “Is axitinib the preferred second-line agent for renal cell carcinoma?” Community Oncology 9, no. 7 (July 1, 2012): 212–13. https://doi.org/10.1016/j.cmonc.2012.07.001.Full Text
-
Lassen, M. R., W. Fisher, P. Mouret, G. Agnelli, D. George, A. Kakkar, P. Mismetti, A. G. G. Turpie, and A. G. G. SAVE Investigators. “Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.” J Thromb Haemost 10, no. 5 (May 2012): 822–32. https://doi.org/10.1111/j.1538-7836.2012.04701.x.Full Text Link to Item
-
Kelly, William Kevin, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, et al. “Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.” J Clin Oncol 30, no. 13 (May 1, 2012): 1534–40. https://doi.org/10.1200/JCO.2011.39.4767.Full Text Link to Item
-
Zurita, A. J., D. J. George, N. D. Shore, G. Liu, G. Wilding, T. E. Hutson, M. Kozloff, et al. “Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.” Ann Oncol 23, no. 3 (March 2012): 688–94. https://doi.org/10.1093/annonc/mdr349.Full Text Link to Item
-
Agnelli, Giancarlo, Daniel J. George, Ajay K. Kakkar, William Fisher, Michael R. Lassen, Patrick Mismetti, Patrick Mouret, et al. “Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.” N Engl J Med 366, no. 7 (February 16, 2012): 601–9. https://doi.org/10.1056/NEJMoa1108898.Full Text Link to Item
-
Armstrong, A. J., J. D. Turnbull, J. Cobert, T. Jaffe, M. R. Harrison, and D. J. George. “Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 435. https://doi.org/10.1200/jco.2012.30.5_suppl.435.Full Text Link to Item
-
Harrison, Michael Roger, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, and Amy P. Abernethy. “Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 406–406. https://doi.org/10.1200/jco.2012.30.5_suppl.406.Full Text
-
Nabhan, Chadi, Leonard G. Gomella, Todd DeVries, James Boyd Whitmore, Mark Walter Frohlich, and Daniel J. George. “An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study.” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 144–144. https://doi.org/10.1200/jco.2012.30.5_suppl.144.Full Text
-
George, Daniel, and Judd W. Moul. “Emerging treatment options for patients with castration-resistant prostate cancer.” Prostate 72, no. 3 (February 2012): 338–49. https://doi.org/10.1002/pros.21435.Full Text Link to Item
-
Armstrong, A. J., J. W. Moul, and D. J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park, N.Y.) 26, no. 1 (January 1, 2012).
-
Stewart, Suzanne Biehn, Lionel L. Bañez, Cary N. Robertson, Stephen J. Freedland, Thomas J. Polascik, Donghua Xie, Bridget F. Koontz, et al. “Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.” J Urol 187, no. 1 (January 2012): 103–8. https://doi.org/10.1016/j.juro.2011.09.040.Full Text Link to Item
-
Harrison, M. R., and D. J. George. “Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) resistance in metastatic renal cell carcinoma (mRCC): Possible mechanisms and clinical approaches.” European Journal of Clinical and Medical Oncology 3, no. 4 (December 1, 2011): 1–9.
-
Harrison, Michael R., and Daniel J. George. “Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.” Clin Cancer Res 17, no. 18 (September 15, 2011): 5841–43. https://doi.org/10.1158/1078-0432.CCR-11-1768.Full Text Link to Item
-
Hall, Simon J., Laurence Klotz, Allan J. Pantuck, Daniel J. George, James B. Whitmore, Mark W. Frohlich, and Robert B. Sims. “Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.” J Urol 186, no. 3 (September 2011): 877–81. https://doi.org/10.1016/j.juro.2011.04.070.Full Text Link to Item
-
Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, and Mariano A. Garcia-Blanco. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.” Mol Cancer Res 9, no. 8 (August 2011): 997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.Full Text Link to Item
-
George, D. J. “Axitinib bests second-line sorafenib for kidney cancer: Commentary.” Oncology Report, no. JULY-AUGUST (July 1, 2011): 19.
-
Bhatt, R. S., A. J. Zurita, A. O’Neill, A. Norden-Zfoni, L. Zhang, H. K. Wu, P. Y. Wen, et al. “Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.” Br J Cancer 105, no. 1 (June 28, 2011): 112–17. https://doi.org/10.1038/bjc.2011.186.Full Text Link to Item
-
George, D. J. “Benefits and limitations of current treatment strategies in advanced prostate cancer.” Clinical Advances in Hematology and Oncology 9, no. 6 (June 1, 2011): 3–5.
-
George, Daniel J., Philip W. Kantoff, and Daniel W. Lin. “Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.” Clin Adv Hematol Oncol 9, no. 6 (June 2011): 1–11.Link to Item
-
George, Daniel J., Philip W. Kantoff, and Daniel W. Lin. “New and emerging treatments for advanced prostate cancer.” Clin Adv Hematol Oncol 9, no. 6 Suppl 12 (June 2011): 1–15.Link to Item
-
Bitting, Rhonda L., Andrew J. Armstrong, and Daniel J. George. “Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?” Clin Med Insights Oncol 5 (2011): 325–32. https://doi.org/10.4137/CMO.S5977.Full Text Link to Item
-
Stadler, Walter M., George Phillips, Daniel J. George, Susan Halabi, and Eric Small. “Bevacizumab and everolimus in renal cancer: a rational way forward.” J Clin Oncol 28, no. 33 (November 20, 2010): e692–93. https://doi.org/10.1200/JCO.2010.30.7934.Full Text Link to Item
-
George, Daniel. “How does sipuleucel-T alter our clinical practice?” Bju Int 106, no. 7 (October 2010): 945–46. https://doi.org/10.1111/j.1464-410x.2010.09642.x.Full Text Link to Item
-
George, D. J. “Toxicity spikes with first-line RCC drug combination: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 24.
-
Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108–16. https://doi.org/10.1038/pcan.2009.62.Full Text Link to Item
-
Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clin Cancer Res 16, no. 11 (June 1, 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.Full Text Link to Item
-
McDermott, David F., and Daniel J. George. “Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.” Cancer Treat Rev 36, no. 3 (May 2010): 216–23. https://doi.org/10.1016/j.ctrv.2009.12.003.Full Text Link to Item
-
Caire, Arthur A., Leon Sun, Cary N. Robertson, Thomas J. Polascik, Kelly E. Maloney, Daniel J. George, Marva M. Price, et al. “Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.” Urology 75, no. 5 (May 2010): 1122–27. https://doi.org/10.1016/j.urology.2009.06.091.Full Text Link to Item
-
Armstrong, Andrew J., Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, and Susan Halabi. “The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.” Eur J Cancer 46, no. 3 (February 2010): 517–25. https://doi.org/10.1016/j.ejca.2009.11.007.Full Text Link to Item
-
Mohler, James, Robert R. Bahnson, Barry Boston, J Erik Busby, Anthony D’Amico, James A. Eastham, Charles A. Enke, et al. “NCCN clinical practice guidelines in oncology: prostate cancer.” J Natl Compr Canc Netw 8, no. 2 (February 2010): 162–200. https://doi.org/10.6004/jnccn.2010.0012.Full Text Link to Item
-
George, D. J. “Pazopanib okay gives clinicians 6 new drugs for advanced RCC: Commentary.” Oncology Report, no. WINT (December 1, 2009): 6.
-
Kaelin, W. G., and D. J. George. “The molecular biology of kidney cancer and its clinical translation into treatment strategies,” December 1, 2009, 79–97. https://doi.org/10.1007/978-1-59745-332-5_5.Full Text
-
Sun, Leon, Arthur A. Caire, Cary N. Robertson, Daniel J. George, Thomas J. Polascik, Kelly E. Maloney, Philip J. Walther, et al. “Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.” J Urol 182, no. 5 (November 2009): 2242–48. https://doi.org/10.1016/j.juro.2009.07.034.Full Text Link to Item
-
George, D. J. “Bevacizumab + interferon fails to improve overall RCC survival: Commentary.” Oncology Report, no. FALL (September 1, 2009): 27.
-
George, D. J. “Pazopanib halves risk of progression in RCC: Commentary.” Oncology Report, no. FALL (September 1, 2009): 27.
-
Morris, Michael J., Ethan M. Basch, George Wilding, Maha Hussain, Michael A. Carducci, Celestia Higano, Philip Kantoff, et al. “Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.” Clin Genitourin Cancer 7, no. 1 (January 2009): 51–57. https://doi.org/10.3816/CGC.2009.n.009.Full Text Link to Item
-
Armstrong, Andrew J., Patricia Creel, James Turnbull, Cassandra Moore, Tracy A. Jaffe, Sherri Haley, William Petros, et al. “A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.” Clin Cancer Res 14, no. 19 (October 1, 2008): 6270–76. https://doi.org/10.1158/1078-0432.CCR-08-1085.Full Text Link to Item
-
Bazelaire, Cedric de, David C. Alsop, Daniel George, Ivan Pedrosa, Yongyu Wang, M Dror Michaelson, and Neil M. Rofsky. “Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.” Clin Cancer Res 14, no. 17 (September 1, 2008): 5548–54. https://doi.org/10.1158/1078-0432.CCR-08-0417.Full Text Link to Item
-
George, D. J. “Dual antiangiogenesis reduces PSA by 50% in most patients: Commentary.” Oncology Report, no. FALL (September 1, 2008): 41.
-
George, D. J. “First-line sunitinib extends survival in metastatic disease: Commentary.” Oncology Report, no. FALL (September 1, 2008): 44.
-
George, D. J. “HIF levels predict sunitinib response and time to progression: Commentary.” Oncology Report, no. FALL (September 1, 2008): 44.
-
George, D. J. “Everolimus doubles PFS after sorafenib/sunitinib resistance: Commentary.” Oncology Report, no. FALL (September 1, 2008): 43.
-
Rini, Brian I., M Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Thomas E. Hutson, et al. “Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.” J Clin Oncol 26, no. 22 (August 1, 2008): 3743–48. https://doi.org/10.1200/JCO.2007.15.5416.Full Text Link to Item
-
Ellis, Leigh, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, Roxanne Williams-Truax, Monica Mita, et al. “Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.” Clin Cancer Res 14, no. 14 (July 15, 2008): 4500–4510. https://doi.org/10.1158/1078-0432.CCR-07-4262.Full Text Link to Item
-
Ramiah, Veshana, Daniel J. George, and Andrew J. Armstrong. “Clinical endpoints for drug development in prostate cancer.” Curr Opin Urol 18, no. 3 (May 2008): 303–8. https://doi.org/10.1097/MOU.0b013e3282fb7807.Full Text Link to Item
-
Armstrong, Andrew J., and Daniel J. George. “New drug development in metastatic prostate cancer.” Urol Oncol 26, no. 4 (2008): 430–37. https://doi.org/10.1016/j.urolonc.2007.11.006.Full Text Link to Item
-
Chen, Franklin L., Andrew J. Armstrong, and Daniel J. George. “Cell signaling modifiers in prostate cancer.” Cancer J 14, no. 1 (2008): 40–45. https://doi.org/10.1097/PPO.0b013e318161d40f.Full Text Link to Item
-
Motzer, Robert J., M Dror Michaelson, Jonathan Rosenberg, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim A. Margolin, and George Wilding. “Sunitinib efficacy against advanced renal cell carcinoma.” J Urol 178, no. 5 (November 2007): 1883–87. https://doi.org/10.1016/j.juro.2007.07.030.Full Text Link to Item
-
Armstrong, Andrew J., and Daniel J. George. “Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.” Ther Clin Risk Manag 3, no. 5 (October 2007): 877–83.Link to Item
-
Avigan, David E., Baldev Vasir, Daniel J. George, William K. Oh, Michael B. Atkins, David F. McDermott, Philip W. Kantoff, et al. “Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.” J Immunother 30, no. 7 (October 2007): 749–61. https://doi.org/10.1097/CJI.0b013e3180de4ce8.Full Text Link to Item
-
George, D., and J. Verweij. “Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.” Ann Oncol 18 Suppl 10 (September 2007): x1–2. https://doi.org/10.1093/annonc/mdm407.Full Text Link to Item
-
Oudard, S., D. George, J. Medioni, and R. Motzer. “Treatment options in renal cell carcinoma: past, present and future.” Ann Oncol 18 Suppl 10 (September 2007): x25–31. https://doi.org/10.1093/annonc/mdm411.Full Text Link to Item
-
Srinivasan, Ramaprasad, Andrew J. Armstrong, William Dahut, and Daniel J. George. “Anti-angiogenic therapy in renal cell cancer.” Bju Int 99, no. 5 Pt B (May 2007): 1296–1300. https://doi.org/10.1111/j.1464-410X.2007.06834.x.Full Text Link to Item
-
Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer.” Minerva Urol Nefrol 59, no. 1 (March 2007): 11–25.Link to Item
-
Kasibhatla, Mohit, Peter Steinberg, Jeffrey Meyer, Marc S. Ernstoff, and Daniel J. George. “Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.” Clin Genitourin Cancer 5, no. 4 (March 2007): 291–94. https://doi.org/10.3816/CGC.2007.n.007.Full Text Link to Item
-
Atkins, Michael B., Marc S. Ernstoff, Robert A. Figlin, Keith T. Flaherty, Daniel J. George, William G. Kaelin, Eugene D. Kwon, et al. “Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.” Clin Cancer Res 13, no. 2 Pt 2 (January 15, 2007): 667s-670s. https://doi.org/10.1158/1078-0432.CCR-06-2231.Full Text Link to Item
-
George, Daniel J. “Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.” Clin Cancer Res 13, no. 2 Pt 2 (January 15, 2007): 753s-757s. https://doi.org/10.1158/1078-0432.CCR-06-2044.Full Text Link to Item
-
Mendiratta, Prateek, Andrew J. Armstrong, and Daniel J. George. “Current standard and investigational approaches to the management of hormone-refractory prostate cancer.” Rev Urol 9 Suppl 1, no. Suppl 1 (2007): S9–19.Link to Item
-
George, D. J., and C. Moore. “Angiogenesis inhibitors in clinical oncology.” Update on Cancer Therapeutics 1, no. 4 (December 1, 2006): 429–34. https://doi.org/10.1016/j.uct.2006.08.006.Full Text
-
Speca, JoEllen, Sarah Yenser, Patricia Creel, and Daniel George. “Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.” Clin Genitourin Cancer 5 Suppl 1 (December 2006): S24–30. https://doi.org/10.3816/cgc.2006.s.004.Full Text Link to Item
-
Bazelaire, Cedric de, Neil M. Rofsky, Guillaume Duhamel, Jingbo Zhang, M Dror Michaelson, Daniel George, and David C. Alsop. “Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement.” Eur Radiol 16, no. 9 (September 2006): 2083–91. https://doi.org/10.1007/s00330-006-0198-1.Full Text Link to Item
-
Motzer, Robert J., Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, et al. “Sunitinib in patients with metastatic renal cell carcinoma.” Jama 295, no. 21 (June 7, 2006): 2516–24. https://doi.org/10.1001/jama.295.21.2516.Full Text Link to Item
-
Oh, William K., Julia Hayes, Carolyn Evan, Judith Manola, Daniel J. George, Helen Waldron, Meaghan Donovan, et al. “Development of an integrated prostate cancer research information system.” Clin Genitourin Cancer 5, no. 1 (June 2006): 61–66. https://doi.org/10.3816/CGC.2006.n.019.Full Text Link to Item
-
Anscher, M. S., R. Clough, C. N. Robertson, L. R. Prosnitz, P. Dahm, P. Walther, C. F. Donatucci, et al. “Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.” Prostate Cancer Prostatic Dis 9, no. 3 (2006): 254–60. https://doi.org/10.1038/sj.pcan.4500903.Full Text Link to Item
-
Febbo, Phillip G., Aaron Thorner, Mark A. Rubin, Massimo Loda, Philip W. Kantoff, William K. Oh, Todd Golub, and Daniel George. “Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.” Clin Cancer Res 12, no. 1 (January 1, 2006): 152–58. https://doi.org/10.1158/1078-0432.CCR-05-1652.Full Text Link to Item
-
Motzer, Robert J., M Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, et al. “Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.” J Clin Oncol 24, no. 1 (January 1, 2006): 16–24. https://doi.org/10.1200/JCO.2005.02.2574.Full Text Link to Item
-
Favaro, Justin P., and Daniel J. George. “Targeted therapy in renal cell carcinoma.” Expert Opin Investig Drugs 14, no. 10 (October 2005): 1251–58. https://doi.org/10.1517/13543784.14.10.1251.Full Text Link to Item
-
Taplin, Mary-Ellen, Daniel J. George, Susan Halabi, Ben Sanford, Philip G. Febbo, Kristen T. Hennessy, Christos G. Mihos, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.” Urology 66, no. 2 (August 2005): 386–91. https://doi.org/10.1016/j.urology.2005.03.040.Full Text Link to Item
-
Febbo, Phillip G., Jerome P. Richie, Daniel J. George, Massimo Loda, Judith Manola, Sridhar Shankar, Agnieska Szot Barnes, et al. “Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.” Clin Cancer Res 11, no. 14 (July 15, 2005): 5233–40. https://doi.org/10.1158/1078-0432.CCR-05-0299.Full Text Link to Item
-
Li, Haojie, Philip W. Kantoff, Jing Ma, Meir J. Stampfer, and Daniel J. George. “Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.” Cancer Epidemiol Biomarkers Prev 14, no. 6 (June 2005): 1557–61. https://doi.org/10.1158/1055-9965.EPI-04-0456.Full Text Link to Item
-
Oh, William K., Daniel J. George, and Miah Hiang Tay. “Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.” Clin Prostate Cancer 4, no. 1 (June 2005): 61–64. https://doi.org/10.3816/cgc.2005.n.014.Full Text Link to Item
-
Sartor, Oliver, and Daniel George. “Prostate-specific antigen endpoints in hormone-refractory prostate cancer.” Clin Prostate Cancer 4, no. 1 (June 2005): 5–6. https://doi.org/10.3816/cgc.2005.n.006.Full Text Link to Item
-
Moore, Cassandra N., and Daniel J. George. “Update in the management of patients with hormone-refractory prostate cancer.” Curr Opin Urol 15, no. 3 (May 2005): 157–62. https://doi.org/10.1097/01.mou.0000165548.87039.ff.Full Text Link to Item
-
Katz-Brull, Rachel, Neil M. Rofsky, Martina M. Morrin, Ivan Pedrosa, Daniel J. George, M Dror Michaelson, Robert P. Marquis, Michal Maril, Carolina Noguera, and Robert E. Lenkinski. “Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy.” Am J Physiol Renal Physiol 288, no. 4 (April 2005): F637–41. https://doi.org/10.1152/ajprenal.00140.2004.Full Text Link to Item
-
De Bazelaire, Cedric, Neil M. Rofsky, Guillaume Duhamel, M Dror Michaelson, Daniel George, and David C. Alsop. “Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).” Acad Radiol 12, no. 3 (March 2005): 347–57. https://doi.org/10.1016/j.acra.2004.12.012.Full Text Link to Item
-
George, D. J., and J. W. Moul. “Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine.” Oncology Report, no. SPRING (March 1, 2005): 54–55.
-
George, D. J., and J. W. Moul. “Combined GM-CSF/docetaxel beneficial against HR prostate cancer.” Oncology Report, no. SPRING (March 1, 2005): 51–52.
-
George, D. J., and J. W. Moul. “CA9 shown to predict response to IL-2 therapy for renal cell carcinoma.” Oncology Report, no. SPRING (March 1, 2005): 59–60.
-
George, Daniel J., Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.” Clin Cancer Res 11, no. 5 (March 1, 2005): 1815–20. https://doi.org/10.1158/1078-0432.CCR-04-1560.Full Text Link to Item
-
Oh, William K., Elizabeth Hagmann, Judith Manola, Daniel J. George, Timothy D. Gilligan, Joseph O. Jacobson, Matthew R. Smith, Donald S. Kaufman, and Philip W. Kantoff. “A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.” Clin Cancer Res 11, no. 1 (January 1, 2005): 284–89.Link to Item
-
Smith, Matthew R., Judith Manola, Donald S. Kaufman, Daniel George, William K. Oh, Elisabetta Mueller, Susan Slovin, Bruce Spiegelman, Eric Small, and Philip W. Kantoff. “Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.” Cancer 101, no. 7 (October 1, 2004): 1569–74. https://doi.org/10.1002/cncr.20493.Full Text Link to Item
-
Atkins, Michael B., David E. Avigan, Ronald M. Bukowski, Richard W. Childs, Janice P. Dutcher, Tim G. Eisen, Robert A. Figlin, et al. “Innovations and challenges in renal cancer: consensus statement from the first international conference.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6277S-6281S. https://doi.org/10.1158/1078-0432.CCR-040720.Full Text Link to Item
-
Dutcher, Janice P. “Mammalian target of rapamycin inhibition.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6382S-6387S. https://doi.org/10.1158/1078-0432.CCR-050008.Full Text Link to Item
-
Flanigan, Robert C. “Debulking nephrectomy in metastatic renal cancer.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6335S-6341S. https://doi.org/10.1158/1078-0432.CCR-sup-040026.Full Text Link to Item
-
Gordon, Michael S. “Novel antiangiogenic therapies for renal cell cancer.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6377S-6381S. https://doi.org/10.1158/1078-0432.CCR-050007.Full Text Link to Item
-
Kaelin, William G. “The von Hippel-Lindau tumor suppressor gene and kidney cancer.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6290S-6295S. https://doi.org/10.1158/1078-0432.CCR-sup-040025.Full Text Link to Item
-
Lipton, Allan, Alejandro Colombo-Berra, Ronald M. Bukowski, Lee Rosen, Ming Zheng, and Gladys Urbanowitz. “Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6397S-6403S. https://doi.org/10.1158/1078-0432.CCR-040030.Full Text Link to Item
-
Potti, Anil, and Daniel J. George. “Tyrosine kinase inhibitors in renal cell carcinoma.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6371S-6376S. https://doi.org/10.1158/1078-0432.CCR-050014.Full Text Link to Item
-
Stadler, Walter M. “Therapeutic options for variant renal cancer: a true orphan disease.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6393S-6396S. https://doi.org/10.1158/1078-0432.CCR-040032.Full Text Link to Item
-
Yang, James C. “Bevacizumab for patients with metastatic renal cancer: an update.” Clin Cancer Res 10, no. 18 Pt 2 (September 15, 2004): 6367S-6370S. https://doi.org/10.1158/1078-0432.CCR-050006.Full Text Link to Item
-
Abe, Miyako, Judith B. Manola, William K. Oh, Diane L. Parslow, Daniel J. George, Carolyn L. Austin, and Philip W. Kantoff. “Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.” Clin Prostate Cancer 3, no. 1 (June 2004): 49–53. https://doi.org/10.3816/cgc.2004.n.013.Full Text Link to Item
-
Tay, M. -. H., D. S. Kaufman, M. M. Regan, S. B. Leibowitz, D. J. George, P. G. Febbo, J. Manola, et al. “Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.” Ann Oncol 15, no. 6 (June 2004): 974–78. https://doi.org/10.1093/annonc/mdh221.Full Text Link to Item
-
George, Daniel J., Meredith M. Regan, William K. Oh, Miah-Hiang Tay, Judith Manola, Niv Decalo, Stephen Duggan, William C. Dewolf, Philip W. Kantoff, and Glenn J. Bubley. “Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.” Urology 63, no. 2 (February 2004): 327–32. https://doi.org/10.1016/j.urology.2003.09.059.Full Text Link to Item
-
Vonderheide, Robert H., Susan M. Domchek, Joachim L. Schultze, Daniel J. George, Kara M. Hoar, Dih-Yih Chen, Katherine F. Stephans, et al. “Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.” Clin Cancer Res 10, no. 3 (February 1, 2004): 828–39. https://doi.org/10.1158/1078-0432.ccr-0620-3.Full Text Link to Item
-
Downing, Sean R., Kristen T. Hennessy, Miyako Abe, Judith Manola, Daniel J. George, and Philip W. Kantoff. “Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.” Clin Prostate Cancer 2, no. 3 (December 2003): 177–80. https://doi.org/10.3816/cgc.2003.n.027.Full Text Link to Item
-
George, Daniel J., and William G. Kaelin. “The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.” N Engl J Med 349, no. 5 (July 31, 2003): 419–21. https://doi.org/10.1056/NEJMp030061.Full Text Link to Item
-
Majumder, Pradip K., Jen Jen Yeh, Daniel J. George, Phillip G. Febbo, Jennifer Kum, Qi Xue, Rachel Bikoff, et al. “Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.” Proc Natl Acad Sci U S A 100, no. 13 (June 24, 2003): 7841–46. https://doi.org/10.1073/pnas.1232229100.Full Text Link to Item
-
Levine, Ross L., Daniel J. George, and Matthew H. Kulke. “Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma.” Clin Adv Hematol Oncol 1, no. 2 (February 2003): 99–100.Link to Item
-
George, Daniel. “Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.” Adv Exp Med Biol 532 (2003): 141–51. https://doi.org/10.1007/978-1-4615-0081-0_12.Full Text Link to Item
-
Smith, Matthew R., Donald Kaufman, Daniel George, William K. Oh, Maryanne Kazanis, Judith Manola, and Philip W. Kantoff. “Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.” Cancer 95, no. 9 (November 1, 2002): 1864–68. https://doi.org/10.1002/cncr.10844.Full Text Link to Item
-
Aiello, Lloyd Paul, Daniel J. George, Mark T. Cahill, Jun S. Wong, Jerry Cavallerano, Alison L. Hannah, and William G. Kaelin. “Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.” Ophthalmology 109, no. 9 (September 2002): 1745–51. https://doi.org/10.1016/s0161-6420(02)01159-4.Full Text Link to Item
-
George, Daniel J. “Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.” Urology 60, no. 3 Suppl 1 (September 2002): 115–21. https://doi.org/10.1016/s0090-4295(02)01589-3.Full Text Link to Item
-
Carroll, Peter R., Philip W. Kantoff, Steven P. Balk, Myles A. Brown, Anthony V. D’amico, Daniel J. George, Gary D. Grossfeld, et al. “Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.” Urology 60, no. 3 Suppl 1 (September 2002): 1–6. https://doi.org/10.1016/s0090-4295(02)01559-5.Full Text Link to Item
-
D’Amico, Anthony V., Tara Saegaert, Ming-Hui Chen, Andrew A. Renshaw, Daniel George, William Oh, and Philip W. Kantoff. “Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.” Cancer 95, no. 2 (July 15, 2002): 275–80. https://doi.org/10.1002/cncr.10673.Full Text Link to Item
-
Oh, William K., Daniel J. George, and Philip W. Kantoff. “Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.” Cancer 94, no. 3 (February 1, 2002): 686–89. https://doi.org/10.1002/cncr.10269.Full Text Link to Item
-
Oh, William K., Judith Manola, Daniel J. George, Abby Fierman, Pamela Fontaine-Rothe, Stephanie Morrissey, Judith Prisby, et al. “A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.” Cancer Invest 20, no. 2 (2002): 186–91. https://doi.org/10.1081/cnv-120001145.Full Text Link to Item
-
George, D. “Platelet-derived growth factor receptors: a therapeutic target in solid tumors.” Semin Oncol 28, no. 5 Suppl 17 (October 2001): 27–33.Link to Item
-
George, D. J., M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, et al. “An α-particle emitting antibody ([213Bi]J591) for radioimmmunotherapy of prostate cancer.” Prostate Journal 3, no. 1 (September 27, 2001): 1. https://doi.org/10.1046/j.1525-1411.2001.003001001.x.Full Text
-
Oh, W. K., D. J. George, D. S. Kaufman, K. Moss, M. R. Smith, J. P. Richie, and P. W. Kantoff. “Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.” Semin Oncol 28, no. 4 Suppl 15 (August 2001): 40–44. https://doi.org/10.1016/s0093-7754(01)90153-8.Full Text Link to Item
-
George, D. J., S. Halabi, T. F. Shepard, N. J. Vogelzang, D. F. Hayes, E. J. Small, P. W. Kantoff, and P. W. Cancer and Leukemia Group B 9480. “Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.” Clin Cancer Res 7, no. 7 (July 2001): 1932–36.Link to Item
-
George, D. J., T. F. Shepard, J. Ma, E. Giovannucci, P. W. Kantoff, and M. J. Stampfer. “PTEN polymorphism (IVS4) is not associated with risk of prostate cancer.” Cancer Epidemiol Biomarkers Prev 10, no. 4 (April 2001): 411–12.Link to Item
-
George, D. “Platelet-derived growth factor receptors: A therapeutic target in solid tumors.” Seminars in Oncology 28, no. 5 SUPPL. 17 (2001): 27–33.
-
Oh, W. K., D. J. George, D. S. Kaufman, K. Moss, M. R. Smith, J. P. Richie, and P. W. Kantoff. “Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report.” Seminars in Oncology 28, no. 4 SUPPL. 15 (2001): 40–44.
-
Oh, W. K., D. J. George, K. Hackmann, J. Manola, and P. W. Kantoff. “Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.” Urology 57, no. 1 (January 2001): 122–26. https://doi.org/10.1016/s0090-4295(00)00986-9.Full Text Link to Item
-
Kelly, W. K., T. Curley, S. Slovin, G. Heller, J. McCaffrey, D. Bajorin, A. Ciolino, et al. “Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.” J Clin Oncol 19, no. 1 (January 1, 2001): 44–53. https://doi.org/10.1200/JCO.2001.19.1.44.Full Text Link to Item
-
Weeraratna, A. T., J. T. Arnold, D. J. George, A. DeMarzo, and J. T. Isaacs. “Rational basis for Trk inhibition therapy for prostate cancer.” Prostate 45, no. 2 (October 1, 2000): 140–48. https://doi.org/10.1002/1097-0045(20001001)45:2<140::aid-pros8>3.0.co;2-#.Full Text Link to Item
-
Low, R. K., and D. George. “Removal of the entrapped basketed ureteral calculus: a novel technique.” J Urol 163, no. 6 (June 2000): 1863.Link to Item
-
George, D. J., C. A. Dionne, J. Jani, T. Angeles, C. Murakata, J. Lamb, and J. T. Isaacs. “Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).” Cancer Res 59, no. 10 (May 15, 1999): 2395–2401.Link to Item
-
George, D. J., and P. W. Kantoff. “Prognostic indicators in hormone refractory prostate cancer.” Urol Clin North Am 26, no. 2 (May 1999): 303–viii. https://doi.org/10.1016/s0094-0143(05)70070-7.Full Text Link to Item
-
Small, T. N., E. B. Papadopoulos, F. Boulad, P. Black, H. Castro-Malaspina, B. H. Childs, N. Collins, et al. “Comparison of immune reconstitution after unrelated and related T-cell- depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions.” Blood 93, no. 2 (1999): 467–80.
-
Dionne, C. A., A. M. Camoratto, J. P. Jani, E. Emerson, N. Neff, J. L. Vaught, C. Murakata, et al. “Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).” Clin Cancer Res 4, no. 8 (August 1998): 1887–98.Link to Item
-
George, D. J., H. Suzuki, G. S. Bova, and J. T. Isaacs. “Mutational analysis of the TrkA gene in prostate cancer.” Prostate 36, no. 3 (August 1, 1998): 172–80. https://doi.org/10.1002/(sici)1097-0045(19980801)36:3<172::aid-pros5>3.0.co;2-j.Full Text Link to Item
-
Dockery, W. D., D. J. George, and R. Rodriguez. “Splenosis presenting as a mass on digital rectal examination.” J Urol 158, no. 6 (December 1997): 2244. https://doi.org/10.1016/s0022-5347(01)68217-x.Full Text Link to Item
-
Nelson, J. B., S. P. Hedican, D. J. George, A. H. Reddi, S. Piantadosi, M. A. Eisenberger, and J. W. Simons. “Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.” Nat Med 1, no. 9 (September 1995): 944–49. https://doi.org/10.1038/nm0995-944.Full Text Link to Item
-
George, D. J., and P. J. Blackshear. “Membrane association of the myristoylated alanine-rich C kinase substrate (MARCKS) protein appears to involve myristate-dependent binding in the absence of a myristoyl protein receptor.” J Biol Chem 267, no. 34 (December 5, 1992): 24879–85.Link to Item
-
Meadows, L. M., D. J. George, and R. E. Kaufman. “Dissociation of thymidine incorporation and transferrin receptor expression from cell growth and c-myc accumulation in alpha-interferon-treated cells.” J Biol Response Mod 9, no. 2 (April 1990): 212–20.Link to Item
-
Ramalingam, sundhar, David Sermer, Rajan Gupta, Patrick Healy, Yuan Wu, Daniel George, Andrew Armstrong, and M. R. Harrison. “Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ).” Journal of Clinical Oncology 34 (n.d.). https://doi.org/10.1200/JCO.2016.34.15\_suppl.e16601.Full Text Link to Item
-
-
Book Sections
-
Karachaliou, G. S., D. R. Kaye, D. J. George, and T. Zhang. “The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC.” In Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management, 207–20, 2022. https://doi.org/10.1007/978-3-030-80546-3_16.Full Text
-
McNamara, M. A., T. Zhang, M. R. Harrison, and D. J. George. “Cancer of the Kidney.” In Abeloff’s Clinical Oncology, 1361-1381.e4, 2019. https://doi.org/10.1016/B978-0-323-47674-4.00079-7.Full Text
-
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” In Treatment Methods for Early and Advanced Prostate Cancer, 213–19, 2008.
-
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” In Prostate Cancer: Principles and Practice, 865–73, 2005.
-
-
Other Articles
-
Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park), January 2012.Link to Item
-
Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to Order From the Prostate Cancer Treatment Menu? THE CRAWFORD/FLAIG ARTICLE REVIEWED.” Oncology New York. UBM MEDICA, January 1, 2012.Link to Item
-
Inman, Brant A., and Daniel J. George. “Is tumor response important for renal carcinoma?” Eur Urol, January 2011. https://doi.org/10.1016/j.eururo.2010.10.010.Full Text Link to Item
-
George, D. J., and J. W. Moul. “Bevacizumab plus interferon-α improves survival: Commentary.” Oncology Report, September 1, 2007.
-
George, D. J., and J. W. Moul. “Satraplatin boosts progression-free survival in SPARC: Commentary.” Oncology Report, September 1, 2007.
-
Freedland, S. J., D. J. George, and J. W. Moul. “Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Sunitinib and temsirolimus: New standards of care for metastatic RCC? Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Perioperative chemotherapy surprisingly underused for transitional cell carcinoma: Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Salvage chemotherapy yields high cure rate in recurrent germ cell tumors: Comment.” Oncology Report, September 1, 2006.
-
Moul, J. W., S. J. Freedland, and D. J. George. “Peripheral androgen blockage produces durable PSA responses in prostate cancer: Comment.” Oncology Report, September 1, 2006.
-
-
Conference Papers
-
Patierno, Brendon M., Wen-Chi Foo, Tyler Allen, Jason A. Somarelli, Kathryn E. Ware, Santosh Gupta, Sandra Wise, et al. “Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.” In Prostate Cancer Prostatic Dis, 25:513–23, 2022. https://doi.org/10.1038/s41391-021-00460-y.Full Text Open Access Copy Link to Item
-
Koontz, B. F., K. E. Hoffman, T. Oyekunle, D. J. George, T. Zhang, W. R. Berry, W. R. Lee, et al. “Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.” In International Journal of Radiation Oncology, Biology, Physics, 111:e281, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.902.Full Text
-
Powles, Thomas, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, et al. “Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.” In Bmc Cancer, 21:904, 2021. https://doi.org/10.1186/s12885-021-08630-w.Full Text Link to Item
-
Gupta, Santosh, Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus, Daniel J. George, Simon G. Gregory, and Andrew J. Armstrong. “Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.” In Mol Cancer Res, 19:1040–50, 2021. https://doi.org/10.1158/1541-7786.MCR-20-0975.Full Text Link to Item
-
Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 36:92–99, 2021. https://doi.org/10.1007/s11606-020-06124-2.Full Text Link to Item
-
Choueiri, T. K., A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, et al. “PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.” In Ann Oncol, 29 Suppl 8:viii726, 2018. https://doi.org/10.1093/annonc/mdy424.040.Full Text Link to Item
-
George, D. J., A. J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, M. J. Lechuga Frean, and A. Ravaud. “Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.” In Ann Oncol, 29 Suppl 8:viii312, 2018. https://doi.org/10.1093/annonc/mdy283.090.Full Text Link to Item
-
Harrison, M. R., P. G. Davis, M. G. Khouri, R. T. Gupta, A. J. Armstrong, M. A. McNamara, T. Zhang, et al. “EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).” In Ann Oncol, 29 Suppl 8:viii623–24, 2018. https://doi.org/10.1093/annonc/mdy300.064.Full Text Link to Item
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology Biomarkers & Prevention, 27:46–46. AMER ASSOC CANCER RESEARCH, 2018.Link to Item
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells.” In Cancer Epidemiology Biomarkers & Prevention, 27:148–148. AMER ASSOC CANCER RESEARCH, 2018.Link to Item
-
George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.Link to Item
-
Batich, Kristen A., Janet S. Staats, Cliburn Chan, Cecile Krejsa, Daniel J. George, Kent J. Weinhold, and Tian Zhang. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 36:e16519–e16519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e16519.Full Text
-
Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.” In Journal of Clinical Oncology, 36:160–160. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.160.Full Text
-
Battle, Dena, Eric Jonasch, Hans J. Hammers, Ithaar Derweesh, Daniel J. George, Axel Bex, Borje Ljungberg, and Michael D. Staehler. “Patients perspectives on adjuvant therapy in renal cell carcinoma.” In Journal of Clinical Oncology, 36:644–644. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.644.Full Text
-
George, Daniel J., Allan J. Pantuck, Robert J. Motzer, Alain Ravaud, Bernard Escudier, Michael D. Staehler, Lucile Serfass, et al. “S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).” In Journal of Clinical Oncology, 36:633–633. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.633.Full Text
-
George, Daniel J., Colin Hessel, Susan Halabi, Ben L. Sanford, M Dror Michaelson, Olwen Mary Hahn, Meghara K. Walsh, et al. “Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.” In Journal of Clinical Oncology, 36:582–582. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.582.Full Text
-
George, Daniel J., Jean-Francois Martini, Michael D. Staehler, Yen-Hwa Chang, Jan Breza, Jean-Jacques Patard, Robert J. Motzer, et al. “Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.” In Journal of Clinical Oncology, 36:576–576. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.576.Full Text
-
Harshman, Lauren Christine, Maneka Puligandla, Naomi B. Haas, Mohamad Allaf, Charles G. Drake, David F. McDermott, Sabina Signoretti, et al. “A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).” In Journal of Clinical Oncology, 36:TPS710–TPS710. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.tps710.Full Text
-
Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.Full Text
-
McNamara, Megan Ann, Michala Ritz, Bennett Chin, Jorge Oldan, Aseem Anand, Taofik Oyekunle, Monika Anand, Andrew J. Armstrong, and Daniel J. George. “Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 36:222–222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.222.Full Text
-
Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:191–191. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.191.Full Text
-
Zhu, Jason, Matthew D. Tucker, Patrick Healy, Michael Sandon Humeniuk, Casey Jarvis, Daniel J. George, and Andrew J. Armstrong. “Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer.” In Journal of Clinical Oncology, 36:318–318. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.318.Full Text
-
Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” In Eur J Cancer, 81:228–36, 2017. https://doi.org/10.1016/j.ejca.2017.02.030.Full Text Link to Item
-
Pal, Sumanta K., Catherine M. Tangen, Ian Murchie Thompson, Brian M. Shuch, Naomi B. Haas, Daniel J. George, Mark N. Stein, John Joseph Wright, Melissa Plets, and Primo Lara. “A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.” In Journal of Clinical Oncology, 35:TPS4599–TPS4599. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.tps4599.Full Text
-
Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” In Prostate, 77:385–95, 2017. https://doi.org/10.1002/pros.23277.Full Text Link to Item
-
Choueiri, T. K., S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, T. Olencki, et al. “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.” In Annals of Oncology, 27:vi566, 2016. https://doi.org/10.1093/annonc/mdw435.23.Full Text
-
Gong, J., D. George, S. Mhatre, S. W. Lin, A. Surinach, H. Wallen, R. Vohra, J. Simpson, S. Ogale, and S. K. Pal. “Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC).” In Annals of Oncology, 27:vi282, 2016. https://doi.org/10.1093/annonc/mdw373.37.Full Text
-
Ravaud, A., R. J. Motzer, H. S. Pandha, M. Staehler, D. George, A. J. Pantuck, A. Patel, et al. “genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC).” In Annals of Oncology, 27:vi565, 2016. https://doi.org/10.1093/annonc/mdw435.22.Full Text
-
Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” In Prostate Cancer Prostatic Dis, 19:100–106, 2016. https://doi.org/10.1038/pcan.2015.59.Full Text Link to Item
-
Freedman, Jennifer A., Timothy J. Robinson, Bonnie LaCroix, Brendon M. Patierno, Daniel J. George, Bruce A. Sullenger, and Steven R. Patierno. “Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent.” In Cancer Epidemiology, Biomarkers &Amp; Prevention, 25:B18–B18. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7755.disp15-b18.Full Text
-
George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.Full Text
-
Harrison, Michael Roger, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, Ulka N. Vaishampayan, et al. “Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.” In Journal of Clinical Oncology, 34:617–617. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.617.Full Text
-
Kyriakopoulos, Christos, Michael Roger Harrison, Nrupen Anjan Bhavsar, Steven Paul Wolf, Brian Addis Costello, Walter Michael Stadler, Hans J. Hammers, et al. “Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.” In Journal of Clinical Oncology, 34:563–563. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.563.Full Text
-
Nordquist, Luke T., Neal D. Shore, Johann S. De Bono, Shilpa Gupta, William R. Berry, Silke Gillessen, Glenn Liu, et al. “Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.” In Journal of Clinical Oncology, 34:273–273. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.273.Full Text
-
Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Eric M. Richardson, Kathleen A. Johnson, Azah Borham, and Daniel J. George. “The metastatic renal cell carcinoma (MaRCC) Registry: a prospective academic and community-based study of metastatic renal cell cancer patients.” In Bju International, 116:3–4. WILEY-BLACKWELL, 2015.Link to Item
-
Costello, Brian A., Michael R. Harrison, Nrupen A. Bhavsar, Steven P. Wolf, Christos E. Kyriakopoulos, Walter M. Stadler, Hans Joerg Hammers, et al. “Physician treatment selection in the prospective metastatic renal cell cancer (MaRCC) registry.” In Bju International, 116:7–7. WILEY-BLACKWELL, 2015.Link to Item
-
Harrison, Michael R., Nrupen A. Bhavsar, Steve P. Wolf, Brian A. Costello, Walter M. Stadler, Hans Joerg Hammers, Ulka Vaishampayan, et al. “Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.” In Bju International, 116:12–12. WILEY-BLACKWELL, 2015.Link to Item
-
Armstrong, Andrew J., Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Smith, Matthew R., Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, et al. “Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.” In J Clin Oncol, 32:3391–99, 2014. https://doi.org/10.1200/JCO.2013.54.5954.Full Text Link to Item
-
Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.Full Text
-
Mitchell, Aaron Philip, Michael Roger Harrison, Daniel J. George, Amy Pickar Abernethy, Mark S. Walker, and Bradford Richard Hirsch. “Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials.” In Journal of Clinical Oncology, 32:6510–6510. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6510.Full Text
-
Sternberg, Cora N., Gedske Daugaard, Lajos Geczi, Sebastien J. Hotte, Paul N. Mainwaring, Fred Saad, Ciro Souza, et al. “Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.” In Journal of Clinical Oncology, 32:5061–5061. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5061.Full Text
-
Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.Full Text
-
Armstrong, Andrew J., Rhonda Lynn Bitting, Gabor Kemeny, and Daniel J. George. “Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.” In Journal of Clinical Oncology, 32:178–178. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.178.Full Text
-
Signorovitch, J. E., N. J. Vogelzang, S. K. Pal, P. L. Lin, D. J. George, M. K. Wong, Z. Liu, et al. “Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell carcinoma: analysis of two practice-based chart reviews.” In Bju International, 112:1–1. WILEY-BLACKWELL, 2013.Link to Item
-
Wong, M. K., E. Jonasch, S. K. Pal, J. E. Signorovitch, P. L. Lin, Z. Liu, X. Wang, et al. “Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials.” In Bju International, 112:1–1. WILEY-BLACKWELL, 2013.Link to Item
-
Armstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ultra N. Vaishampayan, Jorge A. Garcia, et al. “ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
George, Daniel J., Tracy McGowan, Gedske Daugaard, Thomas W. Flaig, Lajos Geczi, Sebastien J. Hotte, Paul N. Mainwaring, et al. “Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Hussain, Maha, Paul Gettys Corn, M Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Yang Bruce, et al. “Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Scher, Howard I., Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, et al. “An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Sharma, Sunil, Ramesh K. Ramanathan, Daniel J. George, Michelle Quinlan, Swarupa Kulkarni, Alaeddin Homsi, Jeffrey W. Scott, and Jeffrey R. Infante. “A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Reed, Shelby D., Michaela A. Dinan, Yanhong Li, Yinghong Zhang, Lesley H. Curtis, Daniel J. George, and Suzanne B. Stewart. “Resource use and costs in the last year of life among Medicare beneficiaries who died from prostate cancer versus with the disease between 2000 and 2007.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” In Journal of Clinical Oncology, 31:105–105. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.105.Full Text
-
McDermott, David F., Judith Manola, Michael Pins, Keith T. Flaherty, Michael B. Atkins, Janice P. Dutcher, Daniel J. George, Kim Allyson Margolin, and Robert S. DiPaola. “The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).” In Journal of Clinical Oncology, 31:345–345. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.345.Full Text
-
Signorovitch, James E., Nicholas J. Vogelzang, Sumanta Kumar Pal, Peggy L. Lin, Daniel J. George, Michael K. K. Wong, Zhimei Liu, et al. “Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.” In Journal of Clinical Oncology, Vol. 31, 2013.Link to Item
-
Wong, Michael K. K., Eric Jonasch, Sumanta Kumar Pal, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Xufang Wang, et al. “Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.” In Journal of Clinical Oncology, Vol. 31, 2013.Link to Item
-
Armstrong, Andrew J., Michael Haggman, Walter Michael Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, Samuel R. Denmeade, et al. “Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Bitting, Rhonda Lynn, Rengasamy Boominathan, Chandra Rao, Elizabeth Embree, Daniel J. George, Mark C. Connelly, Gabor Kemeny, Mariano Garcia-Blanco, and Andrew J. Armstrong. “Isolation of circulating tumor cells using a novel EMT-based capture method.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
George, Daniel J., Paul G. Corn, M Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Yang Bruce, et al. “Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Gomella, Leonard G., Chadi Nabhan, Todd DeVries, James Boyd Whitmore, Mark Walter Frohlich, and Daniel J. George. “Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Harrison, Michael Roger, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, and Amy Pickar Abernethy. “Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Kelly, William Kevin, Susan Halabi, Michael Anthony Carducci, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, Michael J. Morris, Philip W. Kantoff, J. P. Monk, and Eric Jay Small. “Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Small, Eric Jay, Susan Halabi, Michael Anthony Carducci, Charles J. Ryan, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, et al. “The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Yang, Hongbo, Michael K. K. Wong, James E. Signorovitch, Xufang Wang, Zhimei Liu, Nathan S. Liu, Zhengyun Qi, and Daniel J. George. “Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Mouraviev, Vladimir, Leon Sun, John F. Madden, Janice M. Mayes, Judd W. Moul, Daniel J. George, Philip G. Febbo, and Thomas J. Polascik. “Tumor laterality does not predict biochemical prostate cancer recurrence after radical prostatectomy.” In Journal of Endourology, 21:A216–A216. MARY ANN LIEBERT INC, 2007.Link to Item
-
Polascik, Thomas J., Leon Sun, John F. Madden, Janice M. Mayes, Daniel J. George, Philip G. Febbo, and Vladimir Mouraviev. “Prostate cancer laterality as a rationale for the clinical application of focal ablative therapy: An analysis of 1184 prostatectomy specimens.” In Journal of Endourology, 21:A216–A216. MARY ANN LIEBERT INC, 2007.Link to Item
-
Rini, Brian I., Daniel J. George, M Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Kim Margolin, Thomas E. Hutson, and Charles M. Baum. “Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC).” In Annals of Oncology, 17:144–144. OXFORD UNIV PRESS, 2006.Link to Item
-
Force, J. M., J. V. Heymach, M. H. Kulke, C. S. Fuchs, S. Connors, C. Sidor, D. George, J. P. Eder, J. Folkman, and S. Soker. “Circulating Endothelial Cells as a Surrogate Marker of Antiangiogenic Activity in Patients Treated with Endostatin,” n.d.
-
-
Preprints
-
Butler, William, Colin McDowell, Yiping He, Qing Yang, Spencer Hauck, Yinglu Zhou, Andrew Armstrong, Daniel George, Richard Drake, and Jiaoti Huang. “Rewiring of the N-Glycome with Prostate Cancer Progression and Therapy Resistance.” Research Square Platform LLC, July 20, 2022. https://doi.org/10.21203/rs.3.rs-1831833/v1.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
